AU2002232660A1 - Antiviral agents for treatment of flaviviridae infections - Google Patents
Antiviral agents for treatment of flaviviridae infectionsInfo
- Publication number
- AU2002232660A1 AU2002232660A1 AU2002232660A AU3266002A AU2002232660A1 AU 2002232660 A1 AU2002232660 A1 AU 2002232660A1 AU 2002232660 A AU2002232660 A AU 2002232660A AU 3266002 A AU3266002 A AU 3266002A AU 2002232660 A1 AU2002232660 A1 AU 2002232660A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- prodrug
- acceptable salt
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 112
- 208000004576 Flaviviridae Infections Diseases 0.000 title claims description 81
- 239000003443 antiviral agent Substances 0.000 title description 28
- 150000001875 compounds Chemical class 0.000 claims description 227
- 239000000651 prodrug Substances 0.000 claims description 133
- 229940002612 prodrug Drugs 0.000 claims description 133
- 150000003839 salts Chemical class 0.000 claims description 133
- 238000000034 method Methods 0.000 claims description 127
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 127
- 238000011321 prophylaxis Methods 0.000 claims description 94
- 229910052739 hydrogen Inorganic materials 0.000 claims description 85
- 239000003937 drug carrier Substances 0.000 claims description 84
- 239000003795 chemical substances by application Substances 0.000 claims description 83
- 239000003085 diluting agent Substances 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 82
- 150000002431 hydrogen Chemical group 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 75
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 61
- -1 methylene, monofluoromethylene Chemical group 0.000 claims description 59
- 230000004663 cell proliferation Effects 0.000 claims description 39
- 230000002159 abnormal effect Effects 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 36
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 33
- 125000002252 acyl group Chemical group 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 239000011593 sulfur Chemical group 0.000 claims description 33
- 229910052794 bromium Inorganic materials 0.000 claims description 31
- 241000282414 Homo sapiens Species 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical group 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 229910052740 iodine Inorganic materials 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 20
- HNKKJJHKTPALEK-RACQCECLSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5s)-5-(3-carbamoylphenyl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound NC(=O)C1=CC=CC([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 HNKKJJHKTPALEK-RACQCECLSA-N 0.000 claims description 19
- 230000001028 anti-proliverative effect Effects 0.000 claims description 17
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 229930024421 Adenine Natural products 0.000 claims description 11
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 11
- 229960000643 adenine Drugs 0.000 claims description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- 239000011737 fluorine Substances 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 9
- 150000001336 alkenes Chemical class 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 9
- 238000013160 medical therapy Methods 0.000 claims description 5
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical class CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 118
- 239000000203 mixture Substances 0.000 description 77
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 69
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 58
- 241000711549 Hepacivirus C Species 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 48
- 208000015181 infectious disease Diseases 0.000 description 46
- 239000002777 nucleoside Substances 0.000 description 43
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 32
- 229960000951 mycophenolic acid Drugs 0.000 description 32
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 30
- 241000700605 Viruses Species 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 24
- 235000001968 nicotinic acid Nutrition 0.000 description 23
- 239000011664 nicotinic acid Substances 0.000 description 23
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 22
- 230000000840 anti-viral effect Effects 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 22
- 229960000329 ribavirin Drugs 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 21
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 21
- 208000036142 Viral infection Diseases 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 230000009385 viral infection Effects 0.000 description 20
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 18
- 229960004866 mycophenolate mofetil Drugs 0.000 description 18
- 239000007858 starting material Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 150000001298 alcohols Chemical class 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 11
- 150000003222 pyridines Chemical class 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 150000003857 carboxamides Chemical group 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108060004795 Methyltransferase Proteins 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 101710144111 Non-structural protein 3 Proteins 0.000 description 9
- 108020000999 Viral RNA Proteins 0.000 description 9
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- 239000011570 nicotinamide Substances 0.000 description 8
- 229960003966 nicotinamide Drugs 0.000 description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 description 8
- 125000003835 nucleoside group Chemical group 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 241000710831 Flavivirus Species 0.000 description 7
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000005152 nicotinamide Nutrition 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 7
- 229960003723 tiazofurine Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108091092724 Noncoding DNA Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 6
- AMYUZLUBFKOUEX-JKWAKEATSA-N [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)ethoxy]phosphoryl]methyl]phosphinic acid Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)CP(O)(=O)OCCC1=C(O)C(C(=O)OC2)=C2C(C)=C1OC AMYUZLUBFKOUEX-JKWAKEATSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 241000710777 Classical swine fever virus Species 0.000 description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 5
- 241000710781 Flaviviridae Species 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 241000710778 Pestivirus Species 0.000 description 5
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940029575 guanosine Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 4
- WIYQAQIDVXSPMY-DBIOUOCHSA-N 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]benzamide Chemical compound NC(=O)C1=CC=CC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 WIYQAQIDVXSPMY-DBIOUOCHSA-N 0.000 description 4
- YJQYHFMKGAVKDP-UHFFFAOYSA-N 3-butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione Chemical compound C12=CC=CC(O)=C2C(=O)C(=O)C2=C1C=C(C(=O)CCC)C(C)=C2O YJQYHFMKGAVKDP-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229920001268 Cholestyramine Polymers 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 4
- 206010012310 Dengue fever Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 description 4
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 208000025729 dengue disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000023611 glucuronidation Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 235000013902 inosinic acid Nutrition 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 150000003548 thiazolidines Chemical class 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 3
- 238000004679 31P NMR spectroscopy Methods 0.000 description 3
- SAAMGCIISNTKNO-DBIOUOCHSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC(C#N)=C1 SAAMGCIISNTKNO-DBIOUOCHSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241001118702 Border disease virus Species 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710144128 Non-structural protein 2 Proteins 0.000 description 3
- 101800001020 Non-structural protein 4A Proteins 0.000 description 3
- 101710199667 Nuclear export protein Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000710886 West Nile virus Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229950000844 mizoribine Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002212 purine nucleoside Substances 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 2
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 2
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DCTLYFZHFGENCW-UUOKFMHZSA-N 5'-xanthylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 DCTLYFZHFGENCW-UUOKFMHZSA-N 0.000 description 2
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 2
- UBWZUUUKBOMAPO-KYXWUPHJSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxamide Chemical compound NC(=O)C1=CN=CC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 UBWZUUUKBOMAPO-KYXWUPHJSA-N 0.000 description 2
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- 241000545744 Hirudinea Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 241000187180 Streptomyces sp. Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000005915 ammonolysis reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical class C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000005752 bromopyridines Chemical class 0.000 description 2
- 150000005700 bromopyrimidines Chemical class 0.000 description 2
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 2
- 229950005984 cerulenin Drugs 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001036 exonucleolytic effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 2
- 229940103893 gliotoxin Drugs 0.000 description 2
- 229930190252 gliotoxin Natural products 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical class OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- CEMBNJYZNJLQAM-DBIOUOCHSA-N methyl 6-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 CEMBNJYZNJLQAM-DBIOUOCHSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical class NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 150000004799 α-ketoamides Chemical class 0.000 description 2
- RGDAIGPFYLDYJU-FNCVBFRFSA-N (2r,3r,4s,5r)-2-(2-bromopyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=CN=C1Br RGDAIGPFYLDYJU-FNCVBFRFSA-N 0.000 description 1
- QFIWTXFRPCFBDW-PEBGCTIMSA-N (2r,3r,4s,5r)-2-(2-bromopyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=NC(Br)=C1 QFIWTXFRPCFBDW-PEBGCTIMSA-N 0.000 description 1
- TXUKGZOOVIBSOT-FNCVBFRFSA-N (2r,3r,4s,5r)-2-(2-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=CN=C1Cl TXUKGZOOVIBSOT-FNCVBFRFSA-N 0.000 description 1
- CESFODUIXJHCHW-PEBGCTIMSA-N (2r,3r,4s,5r)-2-(2-chloropyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=NC(Cl)=C1 CESFODUIXJHCHW-PEBGCTIMSA-N 0.000 description 1
- SWVRMYGHUIHXJG-PEBGCTIMSA-N (2r,3r,4s,5r)-2-(3-bromopyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=NC=CC=C1Br SWVRMYGHUIHXJG-PEBGCTIMSA-N 0.000 description 1
- XAAJLIKDNUYCFS-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(3-bromopyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=NC=C1Br XAAJLIKDNUYCFS-ZYUZMQFOSA-N 0.000 description 1
- GUHGBVCJSOWGRO-PEBGCTIMSA-N (2r,3r,4s,5r)-2-(3-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=NC=CC=C1Cl GUHGBVCJSOWGRO-PEBGCTIMSA-N 0.000 description 1
- PVKHOOAXZRUIOF-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(4-bromopyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC(Br)=CC=N1 PVKHOOAXZRUIOF-ZYUZMQFOSA-N 0.000 description 1
- PKMVUHKMPGDJJX-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(4-bromopyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CN=CC=C1Br PKMVUHKMPGDJJX-ZYUZMQFOSA-N 0.000 description 1
- FCHVZUQGAXDEOO-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(4-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC(Cl)=CC=N1 FCHVZUQGAXDEOO-ZYUZMQFOSA-N 0.000 description 1
- NHVFKNKYUIHVBP-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(4-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CN=CC=C1Cl NHVFKNKYUIHVBP-ZYUZMQFOSA-N 0.000 description 1
- FVYHNEYTQMIGAL-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(5-bromopyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=C(Br)C=N1 FVYHNEYTQMIGAL-ZYUZMQFOSA-N 0.000 description 1
- QAXPDZWBXOGVJH-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(5-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=C(Cl)C=N1 QAXPDZWBXOGVJH-ZYUZMQFOSA-N 0.000 description 1
- RWJXKEHLWVOKES-ZYUZMQFOSA-N (2r,3r,4s,5r)-2-(5-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CN=CC(Cl)=C1 RWJXKEHLWVOKES-ZYUZMQFOSA-N 0.000 description 1
- SNYRHBXXTSWGKZ-PEBGCTIMSA-N (2r,3r,4s,5r)-2-(6-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=CC(Cl)=N1 SNYRHBXXTSWGKZ-PEBGCTIMSA-N 0.000 description 1
- DCDNTTKSRCZAGM-PEBGCTIMSA-N (2r,3r,4s,5r)-2-(6-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=C(Cl)N=C1 DCDNTTKSRCZAGM-PEBGCTIMSA-N 0.000 description 1
- ZHRRPVAGHYRVRK-XIWVQZPPSA-N (2r,3s,4r)-2-(hydroxymethyl)-5-(6-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1C1=CC=CC(I)=N1 ZHRRPVAGHYRVRK-XIWVQZPPSA-N 0.000 description 1
- IOLOBKFCECZRCQ-PEBGCTIMSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2-iodopyridin-4-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=NC(I)=C1 IOLOBKFCECZRCQ-PEBGCTIMSA-N 0.000 description 1
- UUQFRNLCUQEPPQ-PEBGCTIMSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(3-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=NC=CC=C1I UUQFRNLCUQEPPQ-PEBGCTIMSA-N 0.000 description 1
- NDUHIVVKZWKQTQ-ZYUZMQFOSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(3-iodopyridin-4-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=NC=C1I NDUHIVVKZWKQTQ-ZYUZMQFOSA-N 0.000 description 1
- XLHPINWVXHILLA-ZYUZMQFOSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(4-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC(I)=CC=N1 XLHPINWVXHILLA-ZYUZMQFOSA-N 0.000 description 1
- PMZXXMMIFPQCAB-ZYUZMQFOSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(4-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CN=CC=C1I PMZXXMMIFPQCAB-ZYUZMQFOSA-N 0.000 description 1
- MMLXOVNHWNQNLG-ZYUZMQFOSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(5-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=C(I)C=N1 MMLXOVNHWNQNLG-ZYUZMQFOSA-N 0.000 description 1
- SJOROZAEYVTQPZ-ZYUZMQFOSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(5-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CN=CC(I)=C1 SJOROZAEYVTQPZ-ZYUZMQFOSA-N 0.000 description 1
- OEFSSAOCAVWWLH-PEBGCTIMSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=C(I)N=C1 OEFSSAOCAVWWLH-PEBGCTIMSA-N 0.000 description 1
- OWIZLXDXHRKVEE-BGZDPUMWSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(2-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CN=C1I OWIZLXDXHRKVEE-BGZDPUMWSA-N 0.000 description 1
- IOLOBKFCECZRCQ-QQRDMOCMSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(2-iodopyridin-4-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC(I)=C1 IOLOBKFCECZRCQ-QQRDMOCMSA-N 0.000 description 1
- UUQFRNLCUQEPPQ-QQRDMOCMSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(3-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=NC=CC=C1I UUQFRNLCUQEPPQ-QQRDMOCMSA-N 0.000 description 1
- NDUHIVVKZWKQTQ-KYXWUPHJSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(3-iodopyridin-4-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC=C1I NDUHIVVKZWKQTQ-KYXWUPHJSA-N 0.000 description 1
- XLHPINWVXHILLA-KYXWUPHJSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(4-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC(I)=CC=N1 XLHPINWVXHILLA-KYXWUPHJSA-N 0.000 description 1
- PMZXXMMIFPQCAB-KYXWUPHJSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(4-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC=C1I PMZXXMMIFPQCAB-KYXWUPHJSA-N 0.000 description 1
- MMLXOVNHWNQNLG-KYXWUPHJSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(5-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(I)C=N1 MMLXOVNHWNQNLG-KYXWUPHJSA-N 0.000 description 1
- SJOROZAEYVTQPZ-KYXWUPHJSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(5-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC(I)=C1 SJOROZAEYVTQPZ-KYXWUPHJSA-N 0.000 description 1
- ZHRRPVAGHYRVRK-QQRDMOCMSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(6-iodopyridin-2-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CC(I)=N1 ZHRRPVAGHYRVRK-QQRDMOCMSA-N 0.000 description 1
- OEFSSAOCAVWWLH-QQRDMOCMSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)-5-(6-iodopyridin-3-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(I)N=C1 OEFSSAOCAVWWLH-QQRDMOCMSA-N 0.000 description 1
- RGDAIGPFYLDYJU-BGZDPUMWSA-N (2s,3r,4s,5r)-2-(2-bromopyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CN=C1Br RGDAIGPFYLDYJU-BGZDPUMWSA-N 0.000 description 1
- QFIWTXFRPCFBDW-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(2-bromopyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC(Br)=C1 QFIWTXFRPCFBDW-QQRDMOCMSA-N 0.000 description 1
- TXUKGZOOVIBSOT-BGZDPUMWSA-N (2s,3r,4s,5r)-2-(2-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CN=C1Cl TXUKGZOOVIBSOT-BGZDPUMWSA-N 0.000 description 1
- CESFODUIXJHCHW-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(2-chloropyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC(Cl)=C1 CESFODUIXJHCHW-QQRDMOCMSA-N 0.000 description 1
- SWVRMYGHUIHXJG-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(3-bromopyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=NC=CC=C1Br SWVRMYGHUIHXJG-QQRDMOCMSA-N 0.000 description 1
- XAAJLIKDNUYCFS-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(3-bromopyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC=C1Br XAAJLIKDNUYCFS-KYXWUPHJSA-N 0.000 description 1
- GUHGBVCJSOWGRO-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(3-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=NC=CC=C1Cl GUHGBVCJSOWGRO-QQRDMOCMSA-N 0.000 description 1
- BMVWNOVAPVDWBJ-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(3-chloropyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC=C1Cl BMVWNOVAPVDWBJ-KYXWUPHJSA-N 0.000 description 1
- PVKHOOAXZRUIOF-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(4-bromopyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC(Br)=CC=N1 PVKHOOAXZRUIOF-KYXWUPHJSA-N 0.000 description 1
- PKMVUHKMPGDJJX-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(4-bromopyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC=C1Br PKMVUHKMPGDJJX-KYXWUPHJSA-N 0.000 description 1
- FCHVZUQGAXDEOO-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(4-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC(Cl)=CC=N1 FCHVZUQGAXDEOO-KYXWUPHJSA-N 0.000 description 1
- NHVFKNKYUIHVBP-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(4-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC=C1Cl NHVFKNKYUIHVBP-KYXWUPHJSA-N 0.000 description 1
- QAXPDZWBXOGVJH-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(5-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C=N1 QAXPDZWBXOGVJH-KYXWUPHJSA-N 0.000 description 1
- RWJXKEHLWVOKES-KYXWUPHJSA-N (2s,3r,4s,5r)-2-(5-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC(Cl)=C1 RWJXKEHLWVOKES-KYXWUPHJSA-N 0.000 description 1
- VIQWRBJHTXDPEE-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(6-bromopyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CC(Br)=N1 VIQWRBJHTXDPEE-QQRDMOCMSA-N 0.000 description 1
- SNYRHBXXTSWGKZ-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(6-chloropyridin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CC(Cl)=N1 SNYRHBXXTSWGKZ-QQRDMOCMSA-N 0.000 description 1
- DCDNTTKSRCZAGM-QQRDMOCMSA-N (2s,3r,4s,5r)-2-(6-chloropyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)N=C1 DCDNTTKSRCZAGM-QQRDMOCMSA-N 0.000 description 1
- BMVWNOVAPVDWBJ-PBVVMKELSA-N (3r,4s,5r)-2-(3-chloropyridin-4-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1C1=CC=NC=C1Cl BMVWNOVAPVDWBJ-PBVVMKELSA-N 0.000 description 1
- QWQDAZKEDHLUPM-XIWVQZPPSA-N (3r,4s,5r)-2-(6-bromopyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1C1=CC=C(Br)N=C1 QWQDAZKEDHLUPM-XIWVQZPPSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ODIRBFFBCSTPTO-UHFFFAOYSA-N 1,3-selenazole Chemical class C1=C[se]C=N1 ODIRBFFBCSTPTO-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- CEHJYEXLKQVWOT-UHFFFAOYSA-N 2,4,6-trihydroxy-3-nitrobenzamide Chemical class NC(=O)C1=C(O)C=C(O)C([N+]([O-])=O)=C1O CEHJYEXLKQVWOT-UHFFFAOYSA-N 0.000 description 1
- FEYDZHNIIMENOB-UHFFFAOYSA-N 2,6-dibromopyridine Chemical compound BrC1=CC=CC(Br)=N1 FEYDZHNIIMENOB-UHFFFAOYSA-N 0.000 description 1
- PBCHIHUDEGCMDM-PEBGCTIMSA-N 2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 PBCHIHUDEGCMDM-PEBGCTIMSA-N 0.000 description 1
- MDLAMZCTMQDMIU-GWOFURMSSA-N 2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC(C#N)=CC=N1 MDLAMZCTMQDMIU-GWOFURMSSA-N 0.000 description 1
- GZCUUHFCGKJMKE-WKJUBOCMSA-N 2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=NC=CC=C1C#N GZCUUHFCGKJMKE-WKJUBOCMSA-N 0.000 description 1
- PBCHIHUDEGCMDM-QQRDMOCMSA-N 2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 PBCHIHUDEGCMDM-QQRDMOCMSA-N 0.000 description 1
- MDLAMZCTMQDMIU-DBIOUOCHSA-N 2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC(C#N)=CC=N1 MDLAMZCTMQDMIU-DBIOUOCHSA-N 0.000 description 1
- GVYLXYAXKHGNAX-KYXWUPHJSA-N 2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 GVYLXYAXKHGNAX-KYXWUPHJSA-N 0.000 description 1
- GVYLXYAXKHGNAX-PBVVMKELSA-N 2-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(C2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 GVYLXYAXKHGNAX-PBVVMKELSA-N 0.000 description 1
- BALXSYQWXWVVJJ-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;phosphoric acid Chemical compound OP(O)(O)=O.O=C1NC(N)=NC2=C1NC=N2 BALXSYQWXWVVJJ-UHFFFAOYSA-N 0.000 description 1
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 1
- QLZBZMRCSNLCAC-GWOFURMSSA-N 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=CN=C1C#N QLZBZMRCSNLCAC-GWOFURMSSA-N 0.000 description 1
- AHHKMJVDGZAXEC-PEBGCTIMSA-N 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AHHKMJVDGZAXEC-PEBGCTIMSA-N 0.000 description 1
- BMRNUGJTBSGEDY-ZYUZMQFOSA-N 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BMRNUGJTBSGEDY-ZYUZMQFOSA-N 0.000 description 1
- QLZBZMRCSNLCAC-DBIOUOCHSA-N 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CN=C1C#N QLZBZMRCSNLCAC-DBIOUOCHSA-N 0.000 description 1
- AHHKMJVDGZAXEC-QQRDMOCMSA-N 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AHHKMJVDGZAXEC-QQRDMOCMSA-N 0.000 description 1
- XCDYZFUBKWPBNO-DBIOUOCHSA-N 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN=CC=C1C#N XCDYZFUBKWPBNO-DBIOUOCHSA-N 0.000 description 1
- BMRNUGJTBSGEDY-KYXWUPHJSA-N 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BMRNUGJTBSGEDY-KYXWUPHJSA-N 0.000 description 1
- XCDYZFUBKWPBNO-QHPFDFDXSA-N 3-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1C1=CN=CC=C1C#N XCDYZFUBKWPBNO-QHPFDFDXSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- JUJRDKAGZJWNEM-ZYUZMQFOSA-N 4-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC([C@@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JUJRDKAGZJWNEM-ZYUZMQFOSA-N 0.000 description 1
- JUJRDKAGZJWNEM-KYXWUPHJSA-N 4-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JUJRDKAGZJWNEM-KYXWUPHJSA-N 0.000 description 1
- DBLMCKYATMLEDA-DBIOUOCHSA-N 4-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=NC=C1C#N DBLMCKYATMLEDA-DBIOUOCHSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- CREUWDKZBPXCTB-GWOFURMSSA-N 5-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=C(C#N)N=C1 CREUWDKZBPXCTB-GWOFURMSSA-N 0.000 description 1
- KEHGEOXHJNPODU-ZYUZMQFOSA-N 5-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KEHGEOXHJNPODU-ZYUZMQFOSA-N 0.000 description 1
- SAAMGCIISNTKNO-GWOFURMSSA-N 5-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CN=CC(C#N)=C1 SAAMGCIISNTKNO-GWOFURMSSA-N 0.000 description 1
- CREUWDKZBPXCTB-DBIOUOCHSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(C#N)N=C1 CREUWDKZBPXCTB-DBIOUOCHSA-N 0.000 description 1
- KEHGEOXHJNPODU-KYXWUPHJSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KEHGEOXHJNPODU-KYXWUPHJSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- RRDOHERGKWQLPV-GWOFURMSSA-N 6-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=CC(C#N)=N1 RRDOHERGKWQLPV-GWOFURMSSA-N 0.000 description 1
- XXWRCZSAYAYIDH-ZYUZMQFOSA-N 6-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC([C@@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 XXWRCZSAYAYIDH-ZYUZMQFOSA-N 0.000 description 1
- RRDOHERGKWQLPV-DBIOUOCHSA-N 6-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CC(C#N)=N1 RRDOHERGKWQLPV-DBIOUOCHSA-N 0.000 description 1
- XXWRCZSAYAYIDH-KYXWUPHJSA-N 6-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 XXWRCZSAYAYIDH-KYXWUPHJSA-N 0.000 description 1
- IRQCNZHBLYUPDG-QHPFDFDXSA-N 6-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carbonitrile Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1C1=CC=C(C#N)C=N1 IRQCNZHBLYUPDG-QHPFDFDXSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000178320 Alfuy virus Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000907515 Apoi virus Species 0.000 description 1
- 241001167018 Aroa Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 125000003603 D-ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000710827 Dengue virus 1 Species 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 241000710872 Dengue virus 3 Species 0.000 description 1
- 241000710844 Dengue virus 4 Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 240000000915 Fagraea fragrans Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710843 Japanese encephalitis virus group Species 0.000 description 1
- 241000178324 Koutango virus Species 0.000 description 1
- 241000710912 Kunjin virus Species 0.000 description 1
- 208000003140 Kyasanur forest disease Diseases 0.000 description 1
- 125000003376 L-ribosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@@H](O1)CO)* 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010024887 Louping ill Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 description 1
- 241001147428 Modoc virus group Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 241000288894 Myotis Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 240000003492 Neolamarckia cadamba Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 241001147430 Ntaya virus group Species 0.000 description 1
- 102100025193 OTU domain-containing protein 4 Human genes 0.000 description 1
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000711558 Pestivirus type 3 Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001337451 Polyblastus cancer Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241001147432 Rio Bravo virus group Species 0.000 description 1
- 208000032108 Russian spring-summer encephalitis Diseases 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 241000907519 Saboya virus Species 0.000 description 1
- 241001147424 Seaborne tick-borne virus group Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000178332 Stratford virus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000907508 Uganda S virus Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000907517 Usutu virus Species 0.000 description 1
- 241000464917 Vieja Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- MKSZAUGMIGSRNS-UHFFFAOYSA-N [2-dodecanoyloxy-3-[hydroxy-[hydroxy-[[5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxypropyl] dodecanoate Chemical compound O1C(COP(O)(=O)OP(O)(=O)OCC(COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)CCC1N1C(=O)NC(=O)C(C)=C1 MKSZAUGMIGSRNS-UHFFFAOYSA-N 0.000 description 1
- CSZPJDXQQYTZCY-UHFFFAOYSA-N [Li]C1=CC=CN=C1F Chemical compound [Li]C1=CC=CN=C1F CSZPJDXQQYTZCY-UHFFFAOYSA-N 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical class N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical class O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- SWJQATVEKOWYLB-QCNRFFRDSA-N methyl 2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWJQATVEKOWYLB-QCNRFFRDSA-N 0.000 description 1
- VRPBASPLCOFZMA-GWOFURMSSA-N methyl 2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC([C@@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 VRPBASPLCOFZMA-GWOFURMSSA-N 0.000 description 1
- SWJQATVEKOWYLB-WKJUBOCMSA-N methyl 2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWJQATVEKOWYLB-WKJUBOCMSA-N 0.000 description 1
- VRPBASPLCOFZMA-DBIOUOCHSA-N methyl 2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 VRPBASPLCOFZMA-DBIOUOCHSA-N 0.000 description 1
- WOFADBMQWDKXKR-QCNRFFRDSA-N methyl 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WOFADBMQWDKXKR-QCNRFFRDSA-N 0.000 description 1
- FLZLHBQKSNTOPF-GWOFURMSSA-N methyl 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 FLZLHBQKSNTOPF-GWOFURMSSA-N 0.000 description 1
- WOFADBMQWDKXKR-WKJUBOCMSA-N methyl 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WOFADBMQWDKXKR-WKJUBOCMSA-N 0.000 description 1
- FLZLHBQKSNTOPF-DBIOUOCHSA-N methyl 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 FLZLHBQKSNTOPF-DBIOUOCHSA-N 0.000 description 1
- QJLZZUSRXCOVMT-GWOFURMSSA-N methyl 4-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC([C@@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 QJLZZUSRXCOVMT-GWOFURMSSA-N 0.000 description 1
- KZXSTGOARNZAIK-GWOFURMSSA-N methyl 4-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KZXSTGOARNZAIK-GWOFURMSSA-N 0.000 description 1
- QJLZZUSRXCOVMT-DBIOUOCHSA-N methyl 4-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 QJLZZUSRXCOVMT-DBIOUOCHSA-N 0.000 description 1
- KZXSTGOARNZAIK-DBIOUOCHSA-N methyl 4-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KZXSTGOARNZAIK-DBIOUOCHSA-N 0.000 description 1
- KZXSTGOARNZAIK-QHPFDFDXSA-N methyl 4-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC=C1C1[C@H](O)[C@H](O)[C@@H](CO)O1 KZXSTGOARNZAIK-QHPFDFDXSA-N 0.000 description 1
- SXMNBVQUSNSQHE-GWOFURMSSA-N methyl 5-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SXMNBVQUSNSQHE-GWOFURMSSA-N 0.000 description 1
- SXMNBVQUSNSQHE-DBIOUOCHSA-N methyl 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SXMNBVQUSNSQHE-DBIOUOCHSA-N 0.000 description 1
- RARBNHATRNQTJS-GWOFURMSSA-N methyl 6-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC([C@@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 RARBNHATRNQTJS-GWOFURMSSA-N 0.000 description 1
- CEMBNJYZNJLQAM-GWOFURMSSA-N methyl 6-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 CEMBNJYZNJLQAM-GWOFURMSSA-N 0.000 description 1
- RARBNHATRNQTJS-DBIOUOCHSA-N methyl 6-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 RARBNHATRNQTJS-DBIOUOCHSA-N 0.000 description 1
- CEMBNJYZNJLQAM-QHPFDFDXSA-N methyl 6-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1[C@H](O)[C@H](O)[C@@H](CO)O1 CEMBNJYZNJLQAM-QHPFDFDXSA-N 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002092 orthoester group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical class N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS
FIELD OF THE INVENTION
The present invention includes compounds and methods for the treatment of
Flaviviridae infection such as bovine viral diarrhea virus ("BVDV"), West Nile Virus (WNV) and hepatitis C virus (HCV). This application claims priority to U.S. provisional application 60/256,066 filed on December 15, 2000. Part of this work was supported by
NIH-SBIR grant: 1 R43 CA88578.
BACKGROUND OF THE INVENTION
The Flaviviridae is a group of positive single-stranded RNA viruses with a genome size from 9-15 kb. They are enveloped viruses of approximately 40-50 nm. An overview of the Flaviviridae taxonomy is available from the International Committee for Taxonomy of Viruses. The Flaviviridae consists of three genera.
1. Flaviviruses: This genus includes the Dengue virus group (Dengue virus, Dengue virus type 1, Dengue virus type 2, Dengue virus type 3, Dengue virus type 4), the Japanese encephalitis virus group (Alfuy Virus,
Japanese encephalitis virus, Kookaburra virus, Koutango virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Stratford virus, Usutu virus, West Nile Virus), the Modoc virus group, the Rio Bravo virus group (Apoi virus, Rio Brovo virus, Saboya virus), the Ntaya virus group, the Tick-Borne encephalitis group (tick born encephalitis virus), the Tyuleniy virus group, Uganda S virus group and the Yellow Fever virus group. Apart from these major groups, there are some additional Flaviviruses that are unclassified.
2. Hepaciviruses: This genus contains only one species, the Hepatitis C virus (HCV), which is composed of many clades, types and subtypes.
3. Pestiviruses: This genus includes Bovine Viral Diarrhea Virus-2 (BVDV- 2), Pestivirus type 1 (including BVDV), pestivirus type 2 (including Hog Cholera Virus) and pestivirus type 3 (including Border Disease Virus).
One of the most important Flaviviridae infections in humans is caused by the hepatitis C virus (HCV). This is the second major cause of viral hepatitis, with an estimated 170 million carriers world-wide (World Health Organization; Hepatitis C: global prevalence, Weekly Epidemiological Record, 1997, 72, 341), 3.9 million of whom reside in the United States (Centers for Disease Control; unpublished data, http ://www.cdc.gov/ ncidod/diseases/hepatitis/heptab3.htm) . The genomic organization of the Flaviviridae share many common features. The hepatitis C virus (HCV) genome is often used as a model. HCV is a small, enveloped virus with a positive single-stranded RNA genome of -9.6 kb within the nucleocapsid. The genome contains a single open reading frame (ORF) encoding a polyprotein of just over 3,000 amino acids, which is cleaved to generate the mature structural and nonstructural viral proteins. The ORF is flanked by 5' and 3' non-translated regions
(NTRs) of a few hundred nucleotides in length, which are important for RNA translation and replication. The translated polyprotein contains the structural core (C) and envelope proteins (El, E2, p7) at the N-terminus, followed by the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B). The mature structural proteins are generated via cleavage by the host signal peptidase (see: Hijikata, M. et al. Proc. Nat. Acad. Sci.,
USA, 1991, 88, 5547; Hussy, P. et al. Virology, 1996, 224, 93; Lin, C. et al. J. Virol., 1994, 68, 5063; Mizushima, H. et al. J. Virol, 1994, 68, 2731; Mizushima, H. et al. J. Virol., 1994, 68, 6215; Santolini, E. et al. J. Virol, 1994, 68, 3631; Selby, M. J. et al. Virology, 1994, 204, 114; and Grakoui, A. et al. Proc. Nat. Acad. Sci., USA, 1993, 90, 10538). The junction between NS2 and NS3 is autocatalytically cleaved by the
NS2/NS3 protease (.see: Hijikata, M. et al. J. Virol, 1993, 67, 4665 and Bartenschlager, R. et al. J. Virol, 1994, 68, 5045), while the remaining four junctions are cleaved by the N-terminal serine protease domain of NS3 complex ed with NS4A {see: Failla, C. et al. Virol, 1994, 68, 3753; Lin, C. et al. J. Virol, 1994, 68, 8147; Tanji, Y. et al. J. Virol, 1995, 69, 1575 and Tai, C. L. et al. J. Virol, 1996, 70, 8477). The NS3 protein also contains the Nucleotide Tri-Phosphate-dependent helicase activity which unwinds duplex RNA during replication. The NS5B protein possesses RNA-dependent RNA
polymerase (RDRP) activity {see: Behrens, S. E. et al. EMBO J., 1996, 15, 12; Lohmann, V. et al. J. Virol, 1997, 71, 8416-8428 and Lohmann, V. et al. Virology, 1998, 249, 108), which is essential for viral replication (Ferrari, E. et al. J. Virol, 1999, 73, 1649). It is emphasized here that, unlike HBV or HIV, no DNA is involved in the replication of HCV. Recently in vitro experiments using NS5B, substrate specificity for
HCV-RDRP was studied using guanosine 5'-monophosphate (GMP), 5'-diphosphate (GDP), 5'-triphosphate (GTP) and the 5'-triphosphate of 2'-deoxy and 2',3'-dideoxy guanosine (dGTP and ddGTP, respectively). The authors claimed that HCV-RDRP has a strict specificity for ribonucleoside 5'-triphosphates and requires the 2'- and 3'-OH groups (Lohmann; Virology, 108). Their experiments suggest that the presence of 2'- and 3 '-substituents would be the prerequisite for nucleoside 5'-triphosphates to interact with HCV-RDRP and to act as substrates or inhibitors.
Examples of antiviral agents that have been identified as active against the hepatitis C flavivirus include:
1. interferon and ribavirin (Battaglia, A. M. et al. Ann. Pharmacother. 2000, 34,
487; Berenguer, M. et al. Antivir. Ther. 1998, 3 (Suppl. 3), 125);
2. Substrate-based NS3 protease inhibitors (Attwood et al. PCT WO 98/22496, 1998; Attwood et al. Antiviral Chemistry and Chemotherapy 1999, 10, 259; Attwood et al. German Patent Pub. DE 19914474; Tung et al. PCT WO 98/17679), including alpha-keto-amides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate (Llinas-Brunet et. al. PCT WO 99/07734).
3. Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitiO-benzamide derivatives (Sudo K. et al. Biochemical and Biophysical Research Communications, 1997, 238, 643 and Sudo K. et al. Antiviral Chemistry and
Chemotherapy 1998, 9, 186), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a αrø-phenoxyphenyl group;
4. Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A 5B substrate (Sudo K.
et al. Antiviral Research 1996, 32, 9), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
5. Thiazoli dines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421, 217 and Takeshita N. et al. Analytical Biochemistry 1997, 247, 242;
6. A phenanthrenequinone possessing activity against HCV protease in a SDS- PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al. Tetrahedron Letters 1996, 37, 7229), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu, M. et al.
Bioorganic and Medicinal Chemistry Letters 9, 1949);
7. Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasi , M. A. et al. Biochemistry 1997, 3(5,1598);
8. HCV helicase inhibitors (Diana, G. D. et al. U.S. Patent No. 5,633,358 and Diana, G. D. et al. PCT WO 97/36554);
9. HCV polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari, R. et al. Journal of Virology 1999, 73, 1649), and the natural product cerulenin (Lohmann, V. et al. Virology 1998, 249, 108);
10. Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5' non-coding region (NCR) of the HCV (Alt, M. et al. Hepatology 1995, 22, 707), or nucleotides 326-348 comprising the 3' end of the NCR and nucleotides 371-388 located in the core coding region of the HCV RNA (Alt, M. et al. Archives of Virology 1997, 142, 589 and Galderisi, U. et al. Journal of Cellular Physiology 1999, <°i:2151);
11. Inhibitors of IRES -dependent translation (Ikeda, N et al. Japanese Patent
Publication JP-08268890; Kai, Y. et al. Japanese Patent Publication JP- 10101591);
12. Nuclease-resistant ribozymes (Maccjak, D. J. et al. Hepatology 1999, 30, abstract 995); and
13. Other miscellaneous compounds including 1-amino-alkylcyclohexanes (Gold et al. U.S. Patent No. 6,034,134), alkyl lipids (Chojkier et al. U.S. Patent No. 5,922,757), vitamin E and other antioxidants (Chojkier et al. U.S. Patent No.
5,922,757), squalene, amantadine, bile acids (Ozeki et al. U.S. Patent No. 5,846,964), N-(phosphonoacetyl)-L-aspartic acid, (Diana et al. U.S. Patent No. 5,830,905), benzenedicarboxamides (Diana et al. U.S. Patent No. 5,633,388), polyadenylic acid derivatives (Wang et al. U.S. Patent No. 5,496,546), 2',3'-dideoxyinosine (Yarchoan et al U.S. Patent No. 5,026,687), and benzimidazoles (Colacino et al. U.S. Patent No. 5,891,874).
Inosine Monophosphate Dehydrogenase (IMPDH) Inhibitors
The nicotinamide adenine dinucleotide (NAD)-dependent catalysis of the conversion of inosine-5 '-monophosphate (IMP) to xanthosine-5' -monophosphate (XMP) by the enzyme IMPDH is the rate limiting step in the de novo pathway of guanosine biosynthesis. Rapidly proliferating cells and/or viral infections are heavily dependent on the availability of large nucleotide pools to meet their metabolic requirements. Compounds blocking this de novo biosynthesis pathway will act selectively on these cell types and leave the other ones substantially unaffected. For example, nucleotide pool production via the salvage pathway alone is sufficient for neural cell and kidney-tissue cell proliferation but not for lymphocytes or cancer cells (Allison, A.C., Eugui, E.M. Transplant. Proc, 1994, 26, 3205). As a consequence of these cell requirements, IMPDH inhibition is a recognized target for immunosuppression, anti-cancer treatment and viral chemotherapy. The biochemical mechanism and structural aspects of enzymatic catalysis and inhibition have been recently reviewed (Hedstrom, L. Curr.
Med. Chem., 1999, 6, 545; Goldstein, B.M., Colby, T.D. Curr. Med. Chem., 1999, 6, 519).
There are currently three LMPDH inhibitors on the market. The nucleosides
Ribavirin and Mizoribine (Bredinin) are used clinically as antiviral and immunosuppressive drugs, respectively. The non-nucleoside agent mycophenolate
mofetil (MMF) is an immunosuppressant used in combination with calcineurin inhibitors such as cyclosporin A or FK-506 in many treatment regimens for the prophylaxis of transplant rejection (Mele, T.S., Halloran, P.F. hnmunopharmacology, 2000, 47, 215). These IMPDH inhibitors are typically not used in monotherapy because their efficacious dosing is limited by adverse events, in particular Gl or bone marrow toxicity. These toxicities result either from lack of enzyme specificity or unfavorable pharmacokinetics.
The nucleosides require metabolic activation to the corresponding 5'- onophosphates, which competitively bind to the nucleotide site of IMPDH (IMP). Because nucleotide-binding domains are conserved among many enzymes, the action of Ribavirin and Mizoribin is not IMPDH specific. Ribavirin's interaction with guanine monophosphate reductase, guanine phosphoribosyl transferase, deoxycytidine kinase and thymidine kinase has been reported (Prajda, N., Hata, Y., Abonyi, M., Singhal, R.L., Weber, G. Cancer Res., 1993, 53, 5982). Moreover, these two compounds can be further phosphorylated which allows their interference with additional enzymes or their incorporation into DNA. The reported reversible myelotoxicity of Ribavirin in man is typical of cytotoxic drugs (Canonico, P.G., Kastello, M.D., Spears C.T., Brown, J.R., Jackson, E.A., Jenkins, D.E. Tox. Appl. Pharm., 1984, 74, 155). No toxicology data based on clinical practice with Mizoribin is publicly available (Ishikawa, H. Curr. Med. Chem., 1999, 6, 575). See also Pankiewicz, K.P. Exp. Opin. Ther. Patents, 1999, 9, 55. The non-nucleoside drug mycophenolate mofetil (MMF) is a prodrug of the fungal agent mycophenolic acid (MPA); a highly potent, selective, reversible, noncompetitive IMPDH inhibitor binding at the enzyme's NAD binding site. The favorable activity profile of MMF does not translate into a compound with high clinical efficacy or large therapeutic index. For example, the suppressive effect of MMF on cancer cell lines could not be confirmed in vivo (Tressler, R.J., Garvin, L.J., Slate, D.L.
Int. J. Cancer, 1994, 57,. 568). The relative efficacy of MPA administered on a compassionate-use basis (mean oral dose: 3.7 g/d for the first year followed by 3.0 g/d for >10 years) to psoriasis patients refractory to conventional therapy was limited by a high incidence of Gl toxicity (in 72% of patients during first year) (Epinette, W.W., Parker, CM., Jones, E.L., Greist, M.C. J. Am. Acad. Derm., 1987, 17, 962). Significant clinical improvement has been seen in many MMF-treated rheumatoid arthritis (RA) patients refractory to other disease-modifying anti-rheumatic drugs. Administration of 2
g/d orally b.i.d reduced rheumatoid factor titters in patient peripheral blood (IgG, IgM, IgA titters T-cell number). However, in spite of the low dose used in comparison to the one employed in the psoriasis trial, Gl adverse-effects were again of concern (Grundmann-Kollmann, M., Mooser, G., Schraeder, P., Zollner, T., Kaskel, P., Ochsendorf, F., Boehncke, W.H., Kerscher, M., Kaufmann, R., Peter, R. J. Am. Acad.
Derm., 2000, 42, 835; Goldblum, R. Clin. Exp. Rheumatol, 1993, 11 (Suppl 8), S117). The only indication for which MMF has been approved (2- and 3 g/d given orally b.i.d) is for the prevention of solid transplant organ rejection (Mele, T.S., Halloran, P.F. Immunopharmacology, 2000, 47, 215; European Mycophenolate Mofetil Co-operative Study Group. Transplant. Proc, 1997, 29, 2932). In addition to the presence of Gl adverse effects, a new finding of leukopenia was also observed (Holt, CD., Sievers, T.M., Ghobrial, R.M., Rossi, S.J., Goss, J.A., McDiarmid, SN. BioDrugs, 1998, 10, 373). In spite of its narrow therapeutic index, MMF is widely being used in immunosuppressive regimens for organ transplantation because of the documented substantial reduction of the incidence and intensity of acute organ loss in this life-saving indication.
Numerous pharmacokinetic (PK) investigations have established that MPA, the bioactive component resulting after the rapid and complete enzymatic hydrolysis of orally administered MMF, undergoes extensive enterohepatic recirculation (EHC) (Bullingham, R.E.S., Nicholls, A., Hale, M. Transplant. Proc, 1996, 28, 925).
Approximately 80-90% of MPA is efficiently conjugated into the biologically inactive glucuronide (MPAG) mainly in the liver. MPAG is then excreted into the bile, de- glucuronidated by colonic bacteria and absorbed in the gastrointestinal track (GIT), entering the systemic circulation via the portal flow as MPA. As a result of this pronounced EHC, huge concentrations of MPA are present in the GIT resulting in local damage to the intestinal epithelium. This process is manifested as symptoms including nausea, vomiting, loose bowel movements, abdominal pain and diarrhea. As demonstrated in renal transplanted patients, the PK parameter most closely linked to the pharmacodynamic effect and therapeutic efficacy of MMF is the systemic MPA exposure (area under the time-concentration curve, AUC). Consequently, high doses of
MMF are required to maintain systemic therapeutic levels (Hale, M.D., Nicholls, A.J., Bullingham, R.E.S., Hene, R., Hoitsma, A., Squifflet, J-P., Weimar, W., Vanrenterghem,
Y., Van de Woude, F J., Verspooten, G.A. Clin. Pharmacol. Ther., 1998, 64, 672; Shaw, L.M., Sollinger, H.W., Halloran, P., Morris, R.E., Yatscoff, R.W., Ransom, J., Tsina, I., Keown, P., Holt, D.W., Lieberman, R., Jaklitsch, A., Potter, J. Ther. Drug Monit, 1995, 17, 690). Any process that would tend to decrease the systemic concentration of MPA will also decrease the therapeutic efficacy of MPA. Therefore, it is reasonable to assume that the reported lack of anti-cancer activity of MPA in vivo can be attributed to its rapid removal from the circulation via drastic glucuronidation by cancer cells (Franklin, TJ., Jacobs, V., Jones, G., Pie, P., Bruneau, P. Cancer Res., 1996, 56, 984).
The replacement or protection of the phenolic group to avoid glucuronidation, the modification of the phthalide ring or the replacement of the lactone oxygen was found to be detrimental for potent IMPDH inhibition. Among the numerous derivatives synthesized, the substitution of the methoxy group by an ethyl chain provided a two-fold higher in vitro and 3.5 -fold higher in vivo potency in the murine plaque-forming assay than MPA (Nelson, P.H., Carr, S.F., Devens, B.H., Eugui, E.E., Franco, F., Gonzalez, C, Hawley, R.C., Loughhead, D.G., Milan, D.J., Papp, E., Patterson, J.W., Rouhafza, S.,
Sjogren, E.B., Smith, D.B., Stephenson, R.A., Talamas, F.X., Waltos, A-M., Weikert, R.J., Wu, J.C. J. Med. Chem.,1996, 39, 4181).
The enzymatic activity was also very sensitive to alterations of MPA' s hexenoic chain. While the large majority of these alterations led to compounds of limited biological utility, some interesting MPA derivatives were produced (Nelson, P.H., Eugui,
E., Wang, C.C., Allison, A.C. J. Med. Chem., 1990, 33, 833). For example, the conformationally restricted cyclopentenyl analogue inhibited IMPDH with an IC50 of 8nM versus 20nM for MPA due to the entropic energy gained by locking MPA into its bioactive conformation (Artis, D.R. et al. WO 95/22538). However, the presence of the phenolic function responsible for enterohepatic recirculation, suggests that, in spite of their minor superior potency, no considerable improvement in the therapeutic indexes of these two inhibitors can be expected. Additionally, MPA derivatives carrying at the hexenoic side chain either a-substituents (benzyl, thiomethyl, methoxymethyl, p- hydroxyphenyl, trifluoroacetamido-phenyl) or a methyl at the e-position were shown to be less susceptible to glucuronidation as assessed using the HT29 cell line which rapidly transforms MPA to MPAG. However, their in vitro efficacy was greatly reduced with the exception of the racemic methoxymethyl derivative, which manifest 29% higher in
vitro activity than MPA (Franklin, T.J., Jacobs, V.N., Jones, G., Pie, P. Drug Metab. Disp., 1997, 25, 367). This racemic compound is twice as resistant to glucuronidation as MPA.
In contrast to the structure-activity relationships that can be rationally interpreted based on the architecture of the complex between MPA and IMPDH, the reasons for the resistance of some phenolic compounds to glucuronyltransferases are unclear (Sintchak, M.D., Fleming, M.A., Futer, O., Raybuck, S.A., Chambers, S.P., Caron, P.R., Murcko, M.A., Wilson, K.P. Cell, 1996, 85, 921, Colby, T.D., Vanderveen, K., Strickler, M.D., Markham, G.D., Goldstein, B.M. Proc. Nat. Acad. U.S.A., 1999, 96, 3531). It has been suggested that the additional substituents lead to unfavourable steric interactions with the enzyme's active site (Franklin, T.J., Jacobs, V.N., Jones, G., Pie, P. Drug Metab. Disp., 1997, 25, 367).
In addition to the extensive work aimed at improving the profile of MPA, a recent approach to increase its therapeutic index by influencing the severity of the adverse effects through an alternative galenic formulation has been reported. The sodium salt of
MPA (MPS), in an enteric coated delivery form, coded as ERL080, is currently in phase III clinical studies for the prevention of acute renal allo graft rejection (Haeberlin, B. et al. WO 9738689). This novel formulation is expected to release the drug in or near the small intestine and thus alleviate the adverse effects of MPA related to high local concentrations in the upper GIT such as anorexia, abdominal pain, nausea or vomiting.
The functioning enteric coating of ERL080 was apparent based on the delayed MPA Tmax measured in PK studies carried out in renal transplanted patients (2.0 versus 0.8 hours for MMF) (Schmouder, R., Arns, W., Merkel, F., Schoudrhury, S., Russel, D., Taccard, G. Transplantation, 1999, 67(Suppl), S203). Indeed, the ERL gastro-resistant tablets were rapidly absorbed upon oral administration, leading to systemic MPA exposure bioequivalent to that of MMF capsules. This study also clearly showed that a MPA prodrug form such as MMF is not necessary for the efficient systemic delivery of MPA via the oral route.
Another formulation claimed to improve the therapeutic range of anti- prohferative drugs undergoing EHC, consists of the combination of MMF or MPA with cholestyramine (Lindner, J., et al WO 0033876). Cholestyramine is a non-absorbable, cationic resin that unspecifically binds bile-acids and any large-sized acidic drug such as
MPA and thus blocks the recycling of the parent compound via the EHC route. When cholestyramine was administered to healthy subjects receiving single doses of MMF, exposure to MPA was significantly decreased (mean reduction 37%), this result being consistent with a strong EHC process (Bullingham, R.E.S., Nicholls, A., Hale, M. Transplant. Proc, 1996, 28, 925). Taking into account the established correlation between MPA's pharmacological effects and systemic AUC, a formulation allowing the co-delivery of cholestyramine and MMF would be expected to drastically lower MPA AUC and, consequently, the efficacy of MPA (Hale, M.D., Nicholls, A.J., Bullingham, R.E.S., Hene, R., Hoitsma, A., Squifflet, J-P., Weimar, W., Vanrenterghem, Y., Van de Woude, F.J., Verspooten, G.A. Clin. Pharmacol. Ther., 1998, 64, 672; Shaw, L.M.,
Sollinger, H.W., Halloran, P., Morris, R.E., Yatscoff, R.W., Ransom, J., Tsina, L, Keown, P., Holt, D.W., Lieberman, R., Jaklitsch, A., Potter, J. Ther. Drug Monit., 1995, 17, 690). No pharmacological data resulting from the above combination treatment has been reported. U.S. Patent No. 4,686,234 describes various derivatives of mycophenolic acid, their synthesis and uses in the treatment of autoimmune disorders, psoriasis, and inflammatory diseases, including, in particular, rheumatoid arthritis, tumors, viruses, and for the treatment of allograft rejection.
On May 5, 1995, Morris et al, in U.S. Patent No. 5,665,728, disclosed a method of preventing or treating hyperproliferative vascular disease in a mammal by administering an antiproliferative effective amount of rapamycin alone or in combination with mycophenolic acid.
It is an objective of the present invention to provide compounds, compositions and methods for the treatment or prophylaxis of immunological disorders, prohferative diseases and viral infections in a host.
In addition, in view of the severity of the illnesses associated with Flaviviridae infections, and their pervasiveness in animal and man, it is another object of the present invention to provide compounds, compositions and methods for the treatment or prophylaxis of Flaviviridae infections in a host.
SUMMARY OF INVENTION
The present invention provides compounds, compositions and methods for the treatment or prophylaxis of an immunological disorder, abnormal cellular proliferation or viral infection, and in particular a Flaviviridae infection, including an HCV or a BVDV infection, in a host comprising administering an effective agent of the formula (I):
(I) or its pharmaceutically acceptable salt or prodrug thereof; wherein R is
(DO (HI)
X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;
Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6;
Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8; W'-W4 are same or different, and independently methyne (-CH=)5 azomethyne
(-N=) or sulfur;
W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);
R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine; R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; and
R6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl such as unsubstituted or substituted phenyl or benzyl.
In one embodiment of the present invention, the compound of the general formula (I) is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD).
In addition, truncated compounds chemically modified as discussed below in. order to improve their activity, and in particular antiviral activity, and/or decrease their toxicity are also provided. In particular, the present invention also provides compounds wherein the molecular structures are composed of parts (fragments) of compounds of formula (I), e.g. C2-, C4-, and C6-mycophenolic alcohols, as well as mycophenolic alcohols modified by simple oxidation to the corresponding aldehyde or carboxylic acid derivatives, for example, the following:
or its pharmaceutically acceptable salt or prodrug, wherein each R10 and Rn is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl.
These compounds can be modified by replacement of the alcohol, aldehyde or carboxyl group with the corresponding sulfonyl or phosphoryl functional group.
or its pharmaceutically acceptable salt or prodrug thereof, wherein R10 and R12 are as defined above, and R13 is lower alkyl (i.e. a C1? C2, C3, C , C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C4, C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C4, C5 or C6 alkynyl) or a C3-C8 cycloalkyl.
The parent mycophenolic alcohols can also be reduced to the corresponding alkyl derivatives or dehydrated to the alkenyl or alkynyl derivatives. Non-limiting examples include the following:
or its pharmaceutically acceptable salt or prodrug thereof, wherein R10 is as defined above.
Truncated compounds can be composed of larger fragments such as bis(phosphonate) analogues of mycophenolic alcohols. These compounds may be modified by coupling with another mycophenolic alcohol derivative to give a dimer, e.g. bis-C2MPAlcbis(phosphonate), such as the following:
C4-MPAlcohol-ethyl-n-bis(phosphoπate)
or its pharmaceutically acceptable salt or prodrug thereof, wherein X, R .10 and R 1 12 are as defined above.
The truncated compounds can also be nucleosides such as tiazofurin, benzamide riboside, C-nicotinamide riboside or F-ara-purines (such as F-ara-A).
or its pharmaceutically acceptable salt or prodrug, wherein R can be hydrogen, acyl or silyl.
In a preferred embodiment of the invention, the compounds can be administered in the form of an ether lipid. Alternatively, the phosphonates and phosphoryls can be administered in the form of stabilized phosphate or phospholipid.
The present invention includes at least the following features: a) a compound for the treatment or prophylaxis of a Flaviviridae infection; b) a process for the preparation of the effective agents described herein, their pharmaceutically acceptable salts and prodrugs thereof; c) a pharmaceutical composition that includes an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof together with a pharmaceutically acceptable carrier or diluent according to the present invention for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; d) a pharmaceutical composition that includes an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof in combination with one or more other antivirally effective agents, optionally in a pharmaceutically acceptable carrier or diluent according to the present invention for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDN infection, in a host, and in particular in a human; e) a method for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, including hepatitis C virus or BVDV infection, in a host, and in particular a human, comprising administering an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof; optionally in a pharmaceutically acceptable carrier or diluent; f) a method for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, including hepatitis C virus or BVDV infection, in a host, an in particular a human, comprising administering an effective amount of an agent as described herein, or its pharmaceutically acceptable
salt or prodrug thereof in combination or alternation with one or more other antivirally effective agents, optionally in a pharmaceutically acceptable carrier or diluent; g) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof in medical therapy, i.e. as an antiviral or antiproliferative agent; h) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; i) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human, in combination or alternation with one or more other antivirally effective agents; j) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for use in medical therapy, i.e. as an antiviral or antiproliferative agent; k) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; and 1) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human, in combination or alternation with one or more other antivirally effective agents.
In an additional embodiment, a method for the treatment or prophylaxis of a host, such as a mammal and in particular a human, having a virus-associated disorder which comprises administering to the mammal a pharmaceutically effective amount of one of the described antiviral agents or their pharmaceutically acceptable salts or prodrugs thereof, is provided.
In one particular embodiment, a method for the treatment or prophylaxis of a
Flaviviridae infection, including HCV and BVDV infection, in a host, that includes administering an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent thereof, is provided.
In another particular embodiment, a method for treatment or prophylaxis of a Flaviviridae infections, including HCV and BVDV infection, in a host, that includes administering an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in combination or alternation with one or more other effective agent is provided. hi an additional embodiment, the use of an effective amount of one of the described antiviral agents or their pharmaceutically acceptable salts or prodrugs thereof, for the treatment or prophylaxis of a host, such as a mammal and in particular a human, having a virus-associated disorder is provided.
In one particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent thereof, for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDV infection, in a host is provided.
In another particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in combination or alternation with one or more other effective agent for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDV infection, in a host is provided.
In an additional embodiment, the use of an effective amount of one of the described antiviral agents or their pharmaceutically acceptable salts or prodrugs thereof, in the manufacture of a medicament for the treatment or prophylaxis of a host, such as a mammal and in particular a human, having a virus-associated disorder is provided. In one particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent thereof, in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDV infection, in a host is provided. In another particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in combination or alternation with one or more other effective agent in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDV infection, in a host is provided.
In one embodiment, the antiviral agent has an EC5o (effective concentration to achieve 50% viral inhibition) when tested in an appropriate cell-based assay, of less than 15 micromolar, and more particularly, less than 10 or 5 micromolar.
While the disclosed compounds are illustrated in β-D or β-L configuration, it should be understood that any of the compounds described herein can alternatively be used in the opposite stereoconfiguration, or a mixture thereof. In a preferred embodiment, the selected optical isomer is used in substantially pure form (i.e. approximately 95% pure or greater). For example, any compound illustrated herein in a β-D configuration can also be administered in the β-L configuration, and vice versa. Flaviviruses included within the scope of this invention are discussed generally in
Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott- Raven Publishers, Philadelphia, PA, Chapter 31, 1996. Specific flaviviruses include, without limitation: Absettarov, Alfuy, Apoi, Aroa, Bagaza, Banzi, Bouboui, Bussuquara, Cacipacore, Carey Island, Dakar bat, Dengue 1, Dengue 2, Dengue 3, Dengue 4, Edge Hill, Entebbe bat, Gadgets Gully, Hanzalova, Hypr, Ilheus, Israel turkey meningoencephahtis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou,
Kokobera, Koutango, Kumlinge, Kunjin, Kyasanur Forest disease, Langat, Louping ill, Meaban, Modoc, Montana myotis leukoencephalitis, Murray valley encephalitis, Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom-Penh bat, Powassan, Rio Bravo, Rocio, Royal Farm, Russian spring-summer encephalitis, Saboya, St. Louis encephalitis, Sal Vieja, San Perlita, Saumarez Reef, Sepik, Sokuluk, Spondweni,
Stratford, Tembusu, Tyuleniy, Uganda S, Usutu, Wesselsbron, West Nile, Yaounde, Yellow fever, and Zika.
Pestiviruses included within the scope of this invention are discussed generally in
Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott- Raven Publishers, Philadelphia, PA, Chapter 33, 1996. Specific pestiviruses include, without limitation: bovine viral diarrhea virus ("BVDV"), classical swine fever virus
("CSFV," also called hog cholera virus), and border disease virus ("BDV").
During the course of the development of any RNA-dependent RNA polymerase (RDRP) antiviral agent, the inhibitory effect on DNA-dependent RNA polymerase (DDRP) will need to be considered and measured in a sensitive and reproducible way.
Therefore, in one embodiment of the invention, a method is disclosed that allows measuring of small differences in the intra-cellular quantities of the transcripts derived from the different DDRPs and RDRP simultaneously. The method is based upon the single-tube RT-PCR using real-time fluorescent technology of the RNA products derived from the different polymerase enzyme activities.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is an illustration of the de novo synthesis of guanine nucleotides via inosine monophosphate dehydrogenase (IMPDH), mediated by the cofactor nicotinamide adenine dinucleotide (NAD). Figure 2 is an illustration of azole nucleoside isomers that are generated during a condensation reaction as described in Scheme 6.
Figure 3 is a graphical depiction of the effect of increased concentration of Ribavirin on cell viability, i.e. the cytopathic effect of Ribavirin on MDBK cells.
Figure 4 is a graphical depiction of the toxic effects of C2-MAD on Balb/c mice over a ten day treatment period. The line indicated by circular points represents the effect of water; the square 10 mg/kg/day, the triangle 30 mg/kg/day and the diamond 60 mg/kg/day. As indicated, the compound does not contribute to significant weight gain or loss.
Figure 5 is an illustration of the increase in plaque forming units with increasing concentration of bovine viral diarrhea virus ("BVDV") in cell culture as described in Example 15. Figure 5 establishes that the method of Example 15 provides reliable quantification of BVDV over a four log PFU/mL of virus. Figure 6 is an illustration of the BVDV replication cycle in MDBK cells to determine the optimal harvesting time (in hours post infection versus the log of plaque forming units ("PFU"), i.e. 22 hours after infection, which roughly corresponds to approximately one replication cycle, where the amount of virus produced is equal to the amount of virus inoculated into the cell, as described in Example 16. Figure 7 is a line graph depicting the inhibition of viral production of various concentrations of ribavirin (RIB) and interferon (IFN) relative to no drug over a 4 day incubation period.
Figure 8 is a bar chart graph showing the ability of certain test compounds to inhibit the production of plaque forming units during one replication cycle, as described in Example 17 against BVDV.
Figure 9 is a dose-response curve for C2-MAD relative to ribavirin (Rib) and Tiazofurin. When comparing intracellular viral RNA reduction, ribavirin is more effective than C2-MAD, which is more effective than Tiazofurin. When comparing supernatant viral RNA, a similar pattern is found. Figure 10 is a bar chart graph depicting the competitive effects of exogenous guanosine. The antiviral effect of all the compounds depicted was diminished or reversed with the addition of guanosine, indicating that all compounds are competitive inhibitors of IMPDH.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds, compositions and methods for the treatment or prophylaxis of an immunological disorder, abnormal cellular proliferation or viral infection, and in particular a Flaviviridae infection, including an HCV or a BVDV infection, in a host comprising administering an effective agent of the present invention.
Preferably, the effective agent selectively inhibits inosine monophosphate dehydrogenase (IMPDH) and/or its cofactor, nicotinamide adenine dinucleotide (NAD). The agent can inhibit IMPDH by acting as a substrate analog (inosine monophosphate (IMP) analog), blocking the NAD binding site, or acting as an NAD analog. In one embodiment of the present invention, the effective antiviral agent does not require in vitro or in vivo activation to be an inhibitor.
In an alternate embodiment of the present invention, the effective antiviral agent requires in vitro or in vivo activation to become an inhibitor. Non-limiting examples of necessary activation include phosphorylation, such as with ribavarin and mizoribine wherein phosphorylation to the monophosphate is necessary to inhibit IMPDH, or conversion into the adenine dinucleotide, as with tiazofurin and benzamide riboside wherein conversion into the adenine dinucleotide TAD and BAD respectively is necessary to inhibit IMPDH.
The present invention includes at least the following features: a) a compound for the treatment or prophylaxis of a Flaviviridae infection; b) a process for the preparation of the effective agents described herein, their pharmaceutically acceptable salts and prodrugs thereof; c) a pharmaceutical composition that includes an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof together with a pharmaceutically acceptable carrier or diluent according to the present invention for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; d) a pharmaceutical composition that includes an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof in
combination with one or more other antivirally effective agents, optionally in a pharmaceutically acceptable carrier or diluent according to the present invention for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; e) a method for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, including hepatitis C virus or BVDV infection, in a host, and in particular a human, comprising administering an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent; f) a method for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, including hepatitis C virus or BVDV infection, in a host, an in particular a human, comprising administering an effective amount of an agent as described herein, or its pharmaceutically acceptable salt or prodrug thereof in combination or alternation with one or more other antivirally effective agents, optionally in a pharmaceutically acceptable carrier or diluent; g) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof in medical therapy, i.e. as an antiviral or antiproliferative agent; h) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; i) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human, in combination or alternation with one or more other antivirally effective agents;
j) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for use in medical therapy, i.e. as an antiviral or antiproliferative agent; k) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human; and
1) use of an agent, as described herein, or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation and/or viral infection, and in particular a Flaviviridae infection, such as an HCV or BVDV infection, in a host, and in particular in a human, in combination or alternation with one or more other antivirally effective agents. In an additional embodiment, a method for the treatment or prophylaxis of a host, such as a marnmal and in particular a human, having a virus-associated disorder which comprises administering to the mammal a pharmaceutically effective amount of one of the described antiviral agents or their pharmaceutically acceptable salts or prodrugs thereof, is provided. In one particular embodiment, a method for the treatment or prophylaxis of a
Flaviviridae infection, including HCV and BVDV infection, in a host, that includes administering an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent thereof, is provided. In another particular embodiment, a method for treatment or prophylaxis of a
Flaviviridae infections, including HCV and BVDV infection, in a host, that includes administering an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in combination or alternation with one or more other effective agent is provided.
In an additional embodiment, the use of an effective amount of one of the described antiviral agents or their pharmaceutically acceptable salts or prodrugs thereof, for the treatment or prophylaxis of a host, such as a mammal and in particular a human, having a virus-associated disorder is provided. In one particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent thereof, for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDV infection, in a host is provided. In another particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in combination or alternation with one or more other effective agent for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDV infection, in a host is provided. In an additional embodiment, the use of an effective amount of one of the described antiviral agents or their pharmaceutically acceptable salts or prodrugs thereof, in the manufacture of a medicament for the treatment or prophylaxis of a host, such as a mammal and in particular a human, having a virus-associated disorder is provided.
In one particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent thereof, in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection, including
HCV and BVDV infection, in a host is provided.
In another particular embodiment, the use of an antivirally effective amount of one of the described antiviral agents or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in combination or alternation with one or more other effective agent in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection, including HCV and BVDN infection, in a host is provided.
Active Compounds
In one embodiment of the invention, the active compound is of the following formula (I):
(I) or its pharmaceutically acceptable salt or prodrug thereof; wherein R is
(n) (HI)
X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;
Y is hydrogen, halogen (F, CI, Br, I), NH2. NHR6, NR6R7, NHOH, NHOR6, NHNH2j NR6NH2, NHNHR6, SH, SR6, OH or OR6;
Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8;
W]-W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur; W5-W8 are same or different, and independently methyne (-CH=) or azomethyne
(-N=);
R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;
R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; and
R6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl such as unsubstituted or substituted phenyl or benzyl.
In one embodiment of the present invention, the compound of the general formula (I) is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD).
The structures of compounds with general formula (I) are represented by (but not limited to) structures provided below:
In addition, truncated compounds chemically modified as discussed below in order to improve their activity, and in particular antiviral activity, and/or decrease their toxicity are also provided. In particular, the present invention also provides compounds wherein the molecular structures are composed of parts (fragments) of compounds of formula (I), e.g. C2-, C4-, and C6-mycophenolic alcohols, as well as mycophenolic alcohols modified by simple oxidation to the corresponding aldehyde or carboxylic acid derivatives, for example, the following:
or its pharmaceutically acceptable salt or prodrug, wherein each R10 and R11 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl.
These compounds can be modified by replacement of the alcohol, aldehyde or carboxyl group with the corresponding sulfonyl or phosphoryl functional group.
or its pharmaceutically acceptable salt or prodrug thereof, wherein R10 and R12 are as defined above, and R13 is lower alkyl (i.e. a , C2, C3, C4, C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C4, C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C4, C5 or C6 alkynyl) or a C3-C8 cycloalkyl.
The parent mycophenolic alcohols can also be reduced to the corresponding alkyl derivatives or dehydrated to the alkenyl or alkynyl derivatives. Non-limiting examples include the following:
or its pharmaceutically acceptable salt or prodrug thereof, wherein R , 10 is as defined above.
Truncated compounds can be composed of larger fragments such as bis(phosphonate) analogues of mycophenolic alcohols. These compounds may be modified by coupling with another mycophenolic alcohol derivative to give a dimer, e.g. bis-C2MPAlcbis(phosphonate), such as the following:
C -MPAlcohol-ethylenebis(phosphonate)
or its pharmaceutically acceptable salt or prodrug thereof, wherein X, R10 and R12 are as defined above.
The truncated compounds can also be nucleosides such as tiazofurin, benzamide ' riboside, C-nicotinamide riboside or F-ara-purines (such as F-ara-A).
or its pharmaceutically acceptable salt or prodrug, wherein R can be hydrogen, acyl or silyl.
In a preferred embodiment of the invention, the compounds can be administered in the form of an ether lipid. Alternatively, the phosphonates and phosphoryls can be administered in the form of stabilized phosphate or phospholipid.
In one embodiment, the antiviral agent has an EC50 (effective concentration to achieve 50% viral inhibition) when tested in an appropriate cell-based assay, of less than 15 micromolar, and more particularly, less than 10 or 5 micromolar
II. Stereoisomerism and Polymorphism
Compounds of the present invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. The present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein. The optically active forms can be prepared by, for example, resolution of the racemic form by recrystalhzation techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
In one embodiment of the invention, the compounds are provided in substantially pure form (i.e. approximately 95% pure or greater). Optically active forms of the compounds can be prepared using any method known in the art, including by resolution of the racemic form by recrystalhzation techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase.
Examples of methods to obtain optically active materials include at least the following. i) physical separation of crystals - a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers
exist, i.e., the material is a conglomerate, and the. crystals- are visually distinct; ii) simultaneous crystallization - a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state; iii) enzymatic resolutions - a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme; iv) enzymatic asymmetric synthesis - a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer; v) chemical asymmetric synthesis - a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries; vi) diastereomer separations - a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer; vii) first- and second-order asymmetric transformations - a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential . crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the
crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer; viii) kinetic resolutions - this technique refers to the achievement of partial or complete resolution of a racemate (or of. a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions; ix) enantiospecific synthesis from non-racemic precursors - a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis; x) chiral liquid chromatography - a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase
(including via chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions; xi) chiral gas chromatography - a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase; xii) extraction with chiral solvents - a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent; xiii) transport across chiral membranes - a technique whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral
nature of the membrane that allows only one enantiomer of the racemate to pass through.
Chiral chromatography, including simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.
III. Definitions
The term "alkyl," as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon, including but not limited to those of to C16, and specifically includes methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The alkyl group can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, thiol, imine, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfmyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, phosphate, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in
Greene, et al, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
The term "lower alkyl," as used herein, and unless otherwise specified, refers to a C] to C saturated straight, branched, or if appropriate, a cyclic (for example, cyclopropyl) alkyl group, including both substituted and unsubstituted forms.
As used herein, the term "substantially free of or "substantially in the absence of refers to a nucleoside composition that includes at least 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
Similarly, the term "isolated" refers to a compound composition that includes at least 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the compound, the remainder comprising other chemical species or enantiomers.
The term "enantiomerically enriched" is used throughout the specification to describe a compound which includes at least about 95%, preferably at least 96%, more preferably at least 97%, even more preferably, at least 98%, and even more preferably at least about 99% or more of a single enantiomer of that compound. When a nucleoside of a particular configuration (D or L) is referred to in this specification, it is presumed that the nucleoside is an enantiomerically enriched nucleoside, unless otherwise stated.
The term "host," as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including chimpanzees) and humans.
Alternatively, the term "host," as used herein, refers to a multicellular organism in which prohferative disorders can occur, including animals, and preferably a human. Alternatively, the host is any abnormally proliferating cell, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to any cell line that abnormally proliferates, either from natural or unnatural causes
(for example, from genetic mutation or genetic engineering, respectively), and animals, in particular, primates (including chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as bovine viral diarrhea virus in cattle, hog cholera virus in pigs, and border disease virus in sheep).
The term "pharmaceutically acceptable prodrug" is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester or salt of an ester or a related group) of a disclosed compound which, upon administration to a patient, provides the active parent compound. Pharmaceutically acceptable prodrugs, for example, refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. The compounds of this invention either possess antiviral activity such as against Flaviviridae viruses and/or antiproliferative activity, or are metabolized to a compound that exhibits such activity.
IV. Pharmaceutically Acceptable Salts and Prodrugs
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. In particular, examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate. acetate, citrate, nalonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate and α-glycerophosphate. Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate and carbonate salts. Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the compound. A number of prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the compound will increase the stability of the compound. For example, one or more hydrogens on the phosphonate moiety can be replaced with alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed compounds to achieve a desired effect. The active compounds can also be provided as phosphoether lipids or ether lipids, as disclosed in the following references, which are incorporated by reference herein: Kucera, L.S., N. Iyer, E. Leake, A. Raben, Modest E.K., D.L.W., and C. Piantadosi. 1990. "Novel membrane-interactive ether lipid analogs that inhibit infectious HIN-1 production and induce defective virus formation." AIDS Res. Hum. Retro Viruses. 6:491-501; Piantadosi, C, J. Marasco C.J., S.L. Morris-Νatschke, K.L. Meyer, F.
Gumus, J.R. Surles, K.S. Ishaq, L.S. Kucera, Ν. Iyer, CA. Wallen, S. Piantadosi, and EJ. Modest. 1991. "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity." J. Med. Chem. 34:1408.1414; Hosteller, K.Y., D.D. Richman, D.A. Carson, L.M. Stuhmiller, G.M. T. van Wijk, and H. van den Bosch. 1992. "Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in
CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3,-deoxythymidine." Antimicrob. Agents Chemother. 36:2025.2029; Hosetier, K.Y., L.M. Stuhmiller, H.B. Lenting, H. van den Bosch, and D.D. Richman, 1990. "Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides." J. Biol. Chem. 265:61127.
Νonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently incorporated into the compound include U.S. Patent Νos. 5,149,794 (Sep. 22, 1992, Yatvin et al); 5,194,654 (Mar. 16, 1993, Hosteller et al, 5,223,263 (June 29, 1993, Hosteller et al); 5,256,641 (Oct. 26, 1993, Yatvin et al); 5,411,947 (May 2, 1995, Hosteller et al); 5,463,092 (Oct. 31, 1995, Hostetler et al);
5,543,389 (Aug. 6, 1996, Yatvin et al); 5,543,390 (Aug. 6, 1996, Yatvin et al); 5,543,391 (Aug. 6, 1996, Yatvin et al); and 5,554,728 (Sep. 10, 1996; Basava et al), all
of which are incorporated herein by reference. Foreign patent applications that disclose lipophilic substituents that can be attached to the nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, W0 91/18914, W0 93/00910, W0 94/26273, W0 96/15132, EP 0 350 287, EP 93917054.4, and W0 91/19721.
V. Pharmaceutical Compositions
Pharmaceutical compositions that include a β-D or the β-L stereoisomer can be prepared that include the above-described compound or its salt or prodrug in a therapeutically effective amount, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient for treating any of the conditions described herein, including a Flaviviridae infection. The therapeutically effective amount may vary with the infection or condition to be treated, its severity, the treatment regimen to be employed, the pharmacokinetics of the agent used, as well as the patient treated.
In one aspect according to the present invention, the compound according to the present invention is formulated preferably in admixture with a pharmaceutically acceptable carrier. In general, it is preferable to administer the pharmaceutical composition in orally administrable form, but formulations may be administered via parenteral, intravenous, intramuscular, transdermal, buccal, subcutaneous, suppository or other route. Intravenous and intramuscular formulations are preferably administered in sterile saline. One of ordinary skill in the art may modify the formulation within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising its therapeutic activity. In particular, a modification of a desired compound to render it more soluble in water or other vehicle, for example, may be easily accomplished by routine modification (salt formulation, esterification, etc.).
In certain pharmaceutical dosage forms, the prodrug forms of the compound, especially including acylated (including acetylated or other) and ether derivatives, phosphate esters, stabilized phosphates, and various salt forms of the present compounds, are preferred. One of ordinary skill in the art will recognize how to readily modify the
present compound to a prodrug form to facilitate delivery of active compound to a targeted site within the host organism or patient. The artisan also, will take advantage of favorable pharmacokinetic parameters of the prodrug form, where applicable, in delivering the desired compound to a targeted site within the host organism or patient to maximize the intended effect of the compound in the treatment of any of the conditions described herein, including & Flaviviridae infection (such as an HCV infection).
The amount of compound included within therapeutically active formulations, according to the present invention, is an effective amount for treating any of the conditions described herein, including a Flaviviridae infection. In general, a therapeutically effective amount of the present compound in pharmaceutical dosage form usually ranges from about 0.1 mg/kg to about 100 mg/kg or more, depending upon the compound used, the condition or infection treated and the route of administration. For purposes of the present invention, a prophylactically or preventively effective amount of the compositions, according to the present invention, falls within the same concentration range as set forth above for therapeutically effective amount and is usually the same as a therapeutically effective amount.
Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D., B.I.D., etc.) and may include oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration. Enteric-coated oral tablets may also be used to enhance bioavailability and stability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen, as well as the severity of disease in the patient. Oral dosage forms are particularly preferred, because of ease of administration and prospective favorable patient compliance.
To prepare the pharmaceutical compositions according to the present mvention, a therapeutically effective amount of one or more of the compounds according to the present invention is preferably mixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques to produce a dose. A carrier may take a wide variety of forms depending on the form of preparation desired
for administration, e.g., oral or parenteral. In preparing pharmaceutical compositions in oral dosage form, any of the usual pharmaceutical media may be used. Thus, for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives including water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. For solid oral preparations such as powders, tablets, capsules, and for solid preparations such as suppositories, suitable carriers and additives including starches, sugar carriers, such as dextrose, mannitol, lactose and related carriers, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used. If desired, the tablets or capsules may be enteric-coated for sustained release by standard techniques. The use of these dosage forms may significantly impact the bioavailability of the compounds in the patient.
For parenteral formulations, the carrier will usually comprise sterile water or aqueous sodium chloride solution, though other ingredients, including those that aid dispersion, also may be included. Where sterile water is to be used and maintained as sterile, the compositions and carriers must also be sterilized. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
Liposomal suspensions (including liposomes targeted to viral antigens) may also be prepared by conventional methods to produce pharmaceutically acceptable carriers. In particular, this may be appropriate for the delivery of free nucleosides, acyl nucleosides, phosphate ester prodrug forms as well as the bisphosphonate compounds according to the present invention.
In particularly preferred embodiments according to the present invention, the compounds and compositions are used to treat, prevent or delay the onset of any of the conditions described herein, including a Flaviviridae infection. Preferably, to treat, prevent or delay the onset of the condition, the compositions will be administered in oral dosage form in amounts ranging from about 250 micrograms up to about 1 gram or more at least once a day, preferably, or up to four times a day. The present compounds are preferably administered orally, but may be administered parenterally, topically or in suppository form.
The compounds according to the present invention, because of their low toxicity to host cells in certain instances, may be advantageously employed prophylactically to prevent any of the conditions described herein, including a Flaviviridae infection or to prevent the occurrence of clinical symptoms associated with the condition. Thus, the present invention also encompasses methods for the prophylactic treatment of any of the conditions described herein, including a Flaviviridae infection. In this aspect, according to the present invention, the present compositions are used to prevent or delay the onset of any of the conditions described herein, including a Flaviviridae infection (including HCV infection). This prophylactic method comprises administration to a patient in need of such treatment, or who is at risk for the development of any of the conditions described herein, including a Flaviviridae infection, and in particular an HCV infection, an amount of a compound according to the present invention effective for alleviating, preventing or delaying the onset of the condition. It is preferred in this aspect of the present invention that the compound that is used is maximally effective against the condition and exhibits a minimum of toxicity to the patient. In the case of Flaviviridae infection, compounds according to the present invention that may be used to treat these disease states may be administered within the same dosage range for therapeutic treatment (i.e., about 250 micrograms up to 1 gram or more from one to four times per day for an oral dosage form) as a prophylactic agent to prevent the proliferation of a Flaviviridae infection, or alternatively, to prolong the onset of a Flaviviridae infection, which manifests itself in clinical symptoms.
In addition, compounds according to the present invention can be administered in combination or alternation with one or more antiviral, anti-HBV, anti-HCV or anti- herpetic agent or interferon, anti-cancer, antiproliferative or antibacterial agents, including other compounds of the present invention. Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
VI. Combination and Alternation Therapies for the Treatment of HCV Infection
It has been recognized that drug-resistant variants of HCV can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for an enzyme used in the viral replication cycle, and most typically in the case of HCV, the RNA-dependent-RNA polymerase. Recently, it has been demonstrated that the efficacy of a drug against HCV infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principle drug. Alternatively, the pharmacokinetics, biodistribution, or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.
Examples of agents that have been identified as active against the hepatitis C flavivirus, and thus can be used in combination or alternation with one or more agents of formula (I) to (V), or truncated and modified forms thereof, include:
(1) interferon and ribavirin (Battaglia, A. M. et al. Ann. Pharmacother. 2000, 34, 487; Berenguer, M. et al. Antivir. Ther. 1998, 3 (Suppl. 3), 125);
(2) Substrate-based NS3 protease inhibitors (Attwood et al. PCT WO 98/22496, 1998; Attwood et al. Antiviral Chemistry and Chemotherapy 1999, 10, 259, ; Attwood et al. German Patent Pub. DE 19914474; Tung et al. PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate (Llinas-Brunet et. al. PCT WO 99/07734).
(3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro- benzamide derivatives (Sudo K. et al, Biochemical and Biophysical
Research Communications, 1997, 238, 643 and Sudo K. et al Antiviral Chemistry and Chemotherapy 1998, 9, 186), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing
group;
(4) Thiazolidine derivatives that show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudό K. et al. Antiviral Research 1996, 32, 9), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
(5) Thiazolidines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421, 217 and Takeshita N. et al. Analytical Biochemistry 1997, 247, 242;
(6) A phenanthrenequinone possessing activity against HCV protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al. Tetrahedron Letters 1996, 37, 7229), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al, Bioorganic and Medicinal Chemistry Letters 9, 1949);
(7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M.A. et al Biochemistry 1997, 3(5,1598);
(8) HCV helicase inhibitors (Diana G.D. et al, U.S. Pat. No. 5,633,358 and Diana G.D. et al. PCT WO 97/36554);
(9) HCV polymerase inhibitors such as nucleotide analogues, gliotoxin
(Ferrari R. et al. Journal of Virology 1999, 73, 1649), and the natural product cerulenin (Lohmann V. et al Virology 1998, 249, 108);
(10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5' non-coding region (NCR) of the HCV (Alt M. et al Hepatology 1995, 22, 707), or nucleotides 326-
348 comprising the 3' end of the NCR and nucleotides 371-388 located in the core coding region of the HCV RNA (Alt M. et al Archives of Virology 1997, 142, 589 and Galderisi U. et al, Journal of Cellular Physiology 1999, 81 :2151);
(11) hihibitors of IRES-dependent translation (Ikeda N et al Japanese Patent Pub. JP-08268890; Kai Y. et al Japanese Patent Pub. JP-10101591);
(12) Nuclease-resistant ribozymes. (Maccjak D.J. et al, Hepatology 1999, 30, abstract 995); and
(13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes
(Gold et al. U.S. Patent No. 6,034,134), alkyl lipids (Chojkier et al. U.S. Pat. No. 5,922,757), vitamin E and other antioxidants (Chojkier et al. U.S. Pat. No. 5,922,757), squalene, amantadine, bile acids (Ozeki et al. U.S. Pat. No. 5,846,964), N-(phosphonoacetyl)-L-aspartic acid, (Diana et al. U.S. Pat. No. 5,830,905), benzenedicarboxamides (Diana et al. U.S.
Pat. No. 5,633,388), polyadenylic acid derivatives (Wang et al. U.S. Pat. No. 5,496,546), 2',3'-dideoxyinosine (Yarchoan et al U.S. Pat. No. 5,026,687), and benzimidazoles (Colacino et al. U.S. Pat. No. 5,891,874).
VII. Synthetic Protocol
Compounds of formula (I) can be synthesized by the tetraphosphonate bicyclic trisanhydride method (Pankiewicz et al, WO 98/15563). Compounds wherein the R group is of the formula (II) or (III) and their derivatives can be synthesized by modified literature procedures. Compounds of formulae (IV) and (V) and their derivatives can be prepared from mycophenolic acid.
Synthesis of compounds of formula [I] and their derivatives:
A β-D-purine nucleoside 5'-methylenebis(phosphonate) (1, Scheme 1) is treated with 2-7 molar excess, preferably 3-4 molar excess, of dehydrating agent such as dicyclohexylcarbo-diimide (DCC) or other carbodiimide, such as diisopropyl- carbodiimide, l-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride, l-[3-
(dimethylamino)-propyl]-3-ethylcarbodiimide methiodide and the like, in anhydrous solvent, such as pyridine, pycoline, N,N-dimethyl-formamide (DMF), dimethylsulfoxide (DMSO), hexamethylene-phosphoric triamide, preferably pyridine, at a temperature of
from 0 °C to 100 °C, preferably between 20 °C to 60 °C for a period of from 1 hour to 24 hours, preferably 4-8 hours. The progress of the reaction can be monitored by 31P NMR. Formation of P1,P4-disubstituted methylenebis(phosphonic) anhydride 2 is observed first, but the relatively simple signals of 2 disappears with simultaneous dehydration between P1 and P3 forming 3, which is further dehydrate between P2 and P4 to give the bicyclic trisanhydride intermediate 4 (three characteristic multi-signal resonances at -0.5-2.0 ppm, at 6.0-8.0 ppm and at 12.8-17.6 ppm). When the formation of 4 is completed, an alcohol (R-OH) is added to the mixture and heated to a temperature of from 35 °C to 100 °C, preferably from 60 °C to 70 °C, for a period of from 1 hour to 48 hours, preferably from 18 to 24 hours. Nucleophilic attack by the alcohol occurs at P-2 and P-3 to form the open-chain intermediate 5. The reaction can be followed by 31P NMR spectroscopy, which shows much simpler two broad signals centered at 8 and 18 ppm. Intermediate 5 undergoes rapid hydrolysis upon addition of water to the reaction mixture forming the P1,P2-disubstituted methylenebis(phosphonate) product with structure [I]. After concentration of the mixture in vacuo, the residue is chromatographed on a preparative
HPLC column to give the desired product with structure [I],
The β-L counterpart of [I] also can be synthesized by using the β-L purine nucleoside 5'-methylenebis(phosphonate) counterpart of (1).
Scheme 1
Alternatively, an alcohol synthon, ROH, is converted into methylenebis- (phosphonate) 6 (Scheme 2) by a procedure invented by Pankiewicz et al. Compound 6 is further converted in a solvent, preferably pyridine, into bicyclic trisanhydride 9 via Pl,P4-disubstituted methylenebis-(ρhosphonic) anhydride 7 and monocyclic intermediate 8 by the action of a carbodiimide. The sequence of reactions can be followed by 31P NMR spectroscopy. When formation of 9 is completed, a β-D purine nucleoside 10 is added to the reaction mixture to form P1,P2,P3,P4-tetrasubstituted methylenebis(phosphonic) anhydride 11, which is rather sensitive to moisture, and readily hydrolyzed to the desired product with formula [I] with water.
The β-L- counterpart of [I] can be synthesized by using, instead of 10, the corresponding β-L-nucleoside.
Scheme 2
Synthesis of compounds of formula [II] and their derivatives:
For the preparation of a synthon of R-OH wherein R is formula [II], one of the two methods we invented earlier (Kabat et al, J. Med. Chem., 1987, 30, 924-927; Pankiewicz et al, J. Org. Chem., 1988, 53, 3473-3479) or their modified version (Matulic-Adamic, et al, Synthesis, 1997, 38, 203-206) is exploited.
The preferred starting materials for all the processes for the synthesis of a compound of general formula [II] can be subsumed under general formula Ila as follows:
[Ha] wherein W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);
R5 is a halogen (fluorine, chlorine, bromine or iodine), CN, CONH2, CO2Me, CO2Et, or CO2H; and
M is alkali or alkali earth metal such as lithium, sodium, potassium, magnesium or cadmium. The starting material of formula Ila are allowed to react with 2,3,4,5-tetra-O- protected
such as 2,4;3,5-di-O-berιzylidene-α/Je/zjJo-D-ribose (12, Scheme 3). The reaction is carried out in an appropriate solvent such as ethyl ether or tetrahydrofuran or a mixture of these solvents at a temperature range from -90 °C to 60 °C in a period of from 1 hour to 5 days. The molar ratio of the reactants, Ila to aldehydo- D-ribose 12 can be from 1:1 to 1:10, preferably 1:4. Upon completion of the reaction, water is added to decompose excess metal-complex Ila. Condensation product is obtained from the organic layer by removal of the solvent and chromatographic purification of the residue. The product is a mixture oϊaltro isomer (13) and allo isomer (14). The hydroxyl group of the condensation product 13 or 14 is converted into a leaving group by sulfonylation with a common sulfonylating agent, such as mesyl chloride, tosyl chloride, nisyl chloride, triflyl chloride, tresyl chloride or triflic acid anhydride in pyridine or in an inert solvent such as a chlorinated hydrocarbon, such as methylene chloride, chloroform, ethylene chloride and the like, in the presence of base such as pyridine, triethylamme, jo-di-methylpyridine, DBU, DBN or the like. The temperature range of the reaction is from -78 °C to 60 °C, preferably at room temperature in a period of from 1 hour to 5 days. The corresponding product (15 or 16) is treated with a strong organic acid such as methanesulfonic acid, p-toluenesulfonic
acid, trifluoromethanesulfonic acid or trifluoroacetic acid in an inert organic solvent such as chlorinated hydrocarbons at a temperature range of from 0 °C to 60 °C, preferably at room temperature, in a period of from 5 minutes to 24 hours to give the β-C-nucleoside [II] from the altro isomer 15 and the α-C-nucleoside 17 from the allo isomer 16. 2,3,4,5-Di-O-isopropylidene-aldehydo-D-ribose (18) or 2,3,4,5-tetra-O-benzyl-aldehydo-
D-ribose (19) can also be used instead of 12 in the above sequence of reactions. By using 2,4;3,5-tetra-O-protected aldehydo-1-ribose instead of 12, the L-nucleoside counterpart of [II] can be obtained.
The substituent in the aglycon R5 can be converted into the carboxamide function at various stage of the reaction sequence. Thus, when R5 in 13 or 14 is bromine or iodine, they are lithiated with butyllithium in an inert solvent, such as ethyl ether or tetrahydrofuran, or a mixture of inert solvents, such as a mixture of ethyl ether and hexamethylphosphoric triamide, at a temperature range of from -90 °C to 60 °C, preferably from -78 °C to 25 °C in a period of from 5 minutes to 5 hours. The lithiated product is then treated with carbon dioxide to give carboxylic acid (13 or 14, R5 =
COOH), which is esterified by treatment with diazomethane in ether to afford methyl ester (13 or 14, R5 = COOCH3). Conversion of this ester into carboxamide (13 or 14, R5
= CONH2) is performed by treatment of the ester with alcoholic ammonia at a temperature range from 0 °C to 100 °C, preferably at 25 °C, in a period of from 1 hour to 5 days. This halogen to carboxamide conversion can also be performed of molecule [II] and 17.
When R5 of 13 or 14 is carbonitrile (CN), hydration to carboxamide is achieved in aqueous alcohol at reflux temperature with base such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like or strongly basic ion-exchange resin such as Dowex-1 (OH") or Amberlite 400 (OH").
Scheme 3
12 13, R = H 14, R = H 15, R = Ms 16, R = Ms
[ ll ] 17
18 19
The disadvantage of the above procedure is to prepare starting aldehydo-sugar derivatives 12, 18 or 19, which requires large amounts of toxic alkylmercaptan, mercuric chloride and mercuric oxide. An alternative procedure the present authors developed circumvents such problems.
The starting material for the aglycon is again Ila and the glycon is a protected ribo-γ-lactone, e.g., 5-O-t-butyldimethylsilyl-2,3-O-isopropylidene-D-ribonolactone (20, Scheme 4). These reactants are allowed to react in an inert solvent, such as ethyl ether or tefrahydrofuran or a mixture of these solvents at a temperature range from -90 °C to 60 °C, preferably at -78 °C, in a period of from 1 hour to 5 days. The molar ratio of the reactants, Ila to lactone 20 can be from 0.1:1 to 1:10, preferably 1:1. Upon completion
of the reaction, water is added to decompose excess metal-complex Ila. Condensation product is obtained from the organic layer by removal of the solvent and chromatographic purification of the residue. The product is usually the β- anomer 21. In some cases, hydroxyl group of 21 can be directly removed by reduction with triethylsilane in an inert solvent to give an anomeric mixture of [II] and 17. The ratio of anomers formed is depending upon reduction conditions and not quite predictable. The L-nucleoside counterpart of [II] and 17 can be obtained starting from the L-ribonolactone instead of 20.
Scheme 4
[ II ], β-anomer
17, α-anomer
CH3Ph CH-CH3
R = Tr, PhCH2, THP, H3c Si- or H,C- -Si-
CHjP CH3 CH3
In many cases, however, reduction by number of known procedures does not take place. In such cases, 21 is reduced with sodium borohydride or lithium aluminum hydride, preferably sodium borohydride, to a mixture of open-chain altro and allo isomers 22 and 23 (Scheme 5).
Scheme 5
22 26 28
24, R = H
23 27 29
25, R = H
After selective removal of R in 22 and 23 to 24 and 25, respectively, the vicinal diol is protected with isopropylidene, benzylidene, cyclic carbonate, or orthoester group, preferably isopropylidene group to give 26 and 27, respectively. The anomeric hydroxyl group in these compounds can be sulfonylated, preferably mesylated, as described previously to the corresponding products 28 and 29. Upon treatment of the altro isomer 28 with trifluoroacetic acid, the desired β-C-nucleoside [II] is obtained. The allo isomer gives the α-C-nucleoside 17.
Recently, Matulic-Adamic et al. reported that condensation of 2-fluoro-3- lithiopyridine with 20 (R = t-butyldiphenylsilyl) and obtained a single condensation product analogous to 21. They, however, could not remove the anomeric hydroxyl group by reduction with triethylsilane, or any other reducing agents. They treated the condensation product with sodium borohydride in methanol and obtained a mixture of
open-chain compounds analogous to a mixture of 23 and 25. They found that application of Mitsunobu reaction directly to the mixture afforded an anomeric mixture of cyclized compounds. Taking advantage of Matulic-Adamic discovery we treat a mixture of 27 and 28 directly with triphenylphosphine and diethyl azodicarboxylate (Mitsunobu reaction) in an inert solvent such as ethyl ether or tetrahydrofuran to give [II] and 17 with various anomeric ratios depending upon reaction conditions.
Synthesis of compounds of formula [III]:
When W in compounds of formula [III] is nitrogen, synthesis of [III] is performed by condensation of the base Ilia (Scheme 6) with a D-ribosyl derivative 30 in a chlorinated hydrocarbon (methylene chloride or ethylene chloride) or acetonitrile in the presence of Lewis acid (such as tin chloride, titanium chloride or trimethylsilyl trifiate), followed by deprotection. The molar ratio of the reactants, Ilia to sugar 30 can be from 1 :0.5 to 1 :2, preferably 1:1. The temperature for the reaction can be from -10 °C to 100 °C, preferably from 25 °C to 60 °C for a period from 1 hour to 1 week. Upon completion of the reaction, methanol is added to hydrolyze the silyl groups of the product to give 31. The L-nucleoside counterpart of [III] can be obtained when 30 is replaced by the corresponding L-ribosyl derivative.
Scheme 6
30 31 [ HI ]
R = Ac, Bz, Bnl; R5 = halogen, C02Me, CN; X = OCH3, OAc, CI, Br
It should be noted that Ilia is a tetrazole (Wι-W = N; 31 and 32), triazole (W3 or W4 = CH; 33 to 38), imidazole (Wx and W3 = CH; 39 to 40) or pyrazole (W3 and W4 = CH), condensation reaction affords a mixture of isomers (Figure 1). R5 in [IJJ] is readily modified to carboxamide.
When W2 in [Tfl] is methyne (-CH=) and Wi, W3 or W4 is (N or CH), metalated aglycon Illb (Scheme 7) is prepared and condensed with D-ribo-γ-lactone derivative (20) according to the procedure described already with Scheme 4 to give 41, from which the anomeric hydroxyl group is removed to afford 42 by one of the procedures already discussed. The metalated aglycons ITIb can be prepared from the readily available cyclic amide or cyclic urea (43) by treatment with phosphorus oxyhalide (X = CI or Br) to give the corresponding halogeno derivative (44-46), which is then treated with n-or sec- or t- butyllithium in tetrahydrofuran.
Scheme 7
20
Tr, PhCH2, THP, H3c
Illb
43 44 45 46 X = Cl or Br, M = Li or Cd1/2
Compounds of foπnula III can also be synthesized from a ribosyl nitrile or - ribosyl acetonitrile. 2,3-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-β-D-ribosylnitrile (49, Scheme 8) is prepared from the known β-D-ribofuranosylnitrile (47) by isopropyUdenation by treatment with 2,2-dimethoxyproρane in acetone in the presence of catalytic amount of acid, such as sulfuric, p-toluenesulfonic, methanesulfonic or trifluoromethanesulfonic acid, followed by treatment of the product 48 with t- butyldiphenylsilyl chloride in pyridine in the presence of -dimethylaminopyridine.
Instead of using 2,2-dimethoxypropane, when α, -dimethoxytoluene is used in an inert solvent, 2,3-O-benzylidene derivative is formed. Treatment of 47 with cyclohexanone and acid, 2,3-cyclohexylidene derivative is formed instead of 48. These base stable 2,3- di-O-protected intermediates can also be used for the present invention. The 5-position of 48 or an analogue can also be protected with tetrahydropyranyl, benzoyl, t- butyldimethylsilyl or benzyl group. Compound 49 is reduced with sodium borohydride or lithium aluminum hydride or a like in an inert solvent, preferably, tetrahydrofuran, to give the aminomethyl product 50, which is converted into the diazomethane 51 by diazotization. 1,3-Di-polar addition of 51 with methyl propiolate affords the pyrazole derivative 52. Ammonolysis of 52 gives carboxamide derivative 53, which, upon treatment with fluoride ion (tetrabutylammonium fluoride or triethyl-immonium hydrogen fluoride) affords the 2,3-O-iso-propyliene derivative 54, in which only the 5'- hydroxyl group is free. Starting from the β-L-ribofuranosylnitrile in place of 47, the β-L C-nucleoside counterpart of 54 can be prepared. Compound 54 or its β-L counterpart can be used directly in the synthesis of the NAD analogues discussed with Scheme 1.
Scheme 8
Compound 49 is a versatile intermediate. It can be converted into the thioamide
55 (Scheme 9) which is cyclized with alkyl (methyl or ethyl) bromopyruvate in pyridine gives the thiazole C-nucleoside 56. Ammonolysis of the ester 56, followed by fluoride treatment affords the 2',3'-di-O-protected C-nucleoside 57, which can be used directly in the NAD analogue synthesis as discussed with Scheme 1.
In a similar manner, 49 can be converted into ribosylamide or selenamide (the sulfur in 55 is displaced by O or Se), from which oxazole and selenazole analogues 58 and 59, respectively, can be prepared.
Scheme 9
49 55 56
Synthesis of compounds of formulae [IV] and [Vj:
These compounds are synthesized by the procedure reported by Jones and Mills (J. Med. Chem., 1971, 14, 305).
The following examples are illustrative of the processes and products of the present invention, but are not intended to, and should not be interpreted to, limit in any way the invention set forth in the claims that follow thereafter.
EXAMPLES
Anhydrous solvents were purchased from Aldrich Chemical Company, Inc. (Milwaukee). Melting points (mp) were determined on an Electrothermal digit melting point apparatus and are uncorrected. 'H and 13C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed in order to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet), m (multiple.). All J-values are in Hz. Mass spectra were recorded on a JEOL JMS-SX/SX102A/E mass spectrometer. Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA). Analytic TLC was performed on Whatman LK6F silica gel plates, and preparative TLC on Whatman PK5F silica gel plates. Column chromatography was carried out on Silica Gel (Fisher, S733-1) at atmospheric pressure.
Example 1
5-(2,4;3,5-Di-0-benzylidene-D-hexityl)-3-bromopyridine (13 and 14, R = H, R5 = Br, W = N, W5 = W7 = W8 = CH).
To a solution of 3,5-dibromopyridine (1.45 g, 6.12 mmol) in dry ethyl ether (50 mL) is slowly added {ca. 10 min) a solution of n-butyllithium (2.35 mL, 2.6 M solution in «-hexane, 6.12 mmol) below -50 °C under argon atmosphere. After addition is completed, the reaction mixture is further stirred for 15 minutes. The mixture is then cooled to -78 °C and a solution of 2,4;3,5-di-O-beιιzylidene-D-α/Je/r dø-ribose (12, 500 mg, 1.53 mmol) in tetrahydrofuran (5 mL) is added dropwise, and then the reaction mixture is allowed to warm to room temperature. Water (50 mL) is added to the reaction mixture. The organic layer is separated, washed with brine (30 mL x 3), dried over sodium sulfate, and then concentrated in vacuo. The residue is chromatographed on a column of silica gel (20 g) using first methylene chloride and then 10% ethyl ether in methylene chloride as the eluent, to give a slightly yellow product, which is crystallized
from ethanol (420 mg, 52%), mp. 170-174°C. *H NMR (CDC13): δ 3.8-4.4 (5H, m, H- 2',3',4',5',5"), 5.0 (IH, M, H-1'), 5.60, 5.64, 5.71, 5.74 (2H, 4S, benzylidene -CH<), 7.38 (10H, s, Ph), 7.98 (IH, m, H-2), 8.58 (2H, , H-4,5).
This solid is a mixture of 13 and 14. By following the same procedure but using the corresponding aldehydo-D-ribose
(19 and 20) as the starting materials, 5-(2,3;4,5-di-O-isopropylidene-D-hexityl)-3- bromopyrimidine and 5-(2,3,4,5-tetra-O-benzyl-D-hexityl)-3-bromopyridine are also prepared as altro/allo mixtures.
By following the same procedure but using the corresponding bases as the starting materials, the following compounds are also prepared as altro/allo mixtures:
4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-bromopyridine, 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-bromopyridine, 5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-bromopyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-bromopyridine, 6-(2,4;3 ,5-Di-O-benzylidene-D-hexityl)-3 -bromopyridine,
4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-bromopyridine, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-bromopyridine, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-bromopyridine, 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-bromopyridine, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-chloropyridine,
3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-chloropyridine, 5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-chloropyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-chloropyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-chloropyridine, 5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-chloropyridine,
4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-chloropyridine, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-chloropyridine, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-chloropyridine, 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-chloropyridine, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-iodopyridine,
3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-iodopyridine,
5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-iodopyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-iodopyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-iodopyridine, 5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-iodopyridine, 4-(2,4;3 ,5-Di-O-benzylidene-D-hexityl)-3-iodopyridine,
2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-iodopyridine, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-iodopyridine, 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-iodopyridine, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-cyanopyridine, 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-cyanopyridine,
5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-2-cyanopyridine, 5-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-cyanopyridine, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-cyanopyridine,
2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-3-cyanopyridine, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)-4-cyanopyridine, and 3 -(2,4; 3 , 5 -Di-O-benzylidene-D-hexityl)-4-cyanopyridine.
By following the same procedure but using 2,4;3,5-di-O-benzylidene-L- aldehydo-ribose, thye L-counterpart of 13 and 14 are prepared.
Example 2
Methyl 5-(2,4; 3, 5-di-0-benzylidene-D-hexityl)nicotinate (13 and 14, R=H, R5=CC>2CHι,
W6 =N, W5 = W7 = WS = CH).
To a solution of 5-(2,4;3,5-di-O-benzylidene-D-hexityl)-3-bromopyridine (200 mg, 0.43 mmol) in a mixture of hexamethylphosphoric triamide (0.5 mL) and ethyl ether
(5 mL) is added a solution of butyllithium (2 mL of 2.5 M solution in n-hexane, 5 mmol) under argon atmosphere at -78 °C. After the addition, the mixture is stirred at -78 °C for 15 minutes. A large excess of solid carbon dioxide is added, and the mixture is allowed to warm to room temperature. The mixture is acidified by addition of IN hydrochloric
acid to pH 4, and the organic layer is washed with brine (3 5 mL), dried over sodium sulfate. After removal of sodium sulfate by filtration, the filtrate is cooled to 0 °C and treated with a large excess of ethereal diazomethane. Excess diazomethane is then destroyed by addition of acetic acid. The mixture is concentrated in vacuo, and the residue is chromatographed on a silica gel column using -z-hexane-efhyl acetate (7:3) as the eluent. Methyl 5-(2,4;3,5-di-O-benzylidene-D-hexityl)nicotinate is obtained as a mixture of altro/allo epimers (13 and 14, R = H, R5 = CO CH3, W6 = N, W5 = W7 = Wg = CH), 121 mg (65%), mp 175-178 °C. *H NMR (CDC13): δ 3.5-4.4 (5H, m, H- 2',3',4',5',5"), 3.92, 3.94 (3H, 2s, Me ester), 5.11 (IH, m, H-1'), 5.58, 5.65, 5.71, 5.75 (2H, 4s, benzylidene -CH<), 7.37, 7.38 (10H, 2s, Ph), 8.42, 8.83, 9.13 (3H, 3s, pyridine).
By following the same procedure but using the corresponding pyridine intermediates, the following methyl esters are prepared:
Methyl 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinate, Methyl 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinate, Methyl 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinate,
Methyl 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinate, Methyl 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinate, Methyl 5-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinate, Methyl 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinate, Methyl 2-(2,4;3,5-di-O-benzylidene-D-hexityl)isonicotinate, and
Methyl 3-(234;3,5-di-O-benzylidene-D-hexityl)isonicotinate.
By following the same procedure but using the corresponding L-intermediates, the L-counterpart of the above compounds are synthesized.
Example 3
Methyl 5-(2,4;3,5-di-0-benzylidene-D-hexityl)nicotinamide (13 and 14, R = H, R5 =
CONH2, W6 = N, W5 = W7 = W8 = CH).
An altro/allo epimeric mixture of methyl 5-(2,4;3,5-di-O-benzylidene-D-hexityl)- nicotinate (220 mg, 0.48 mmol) is treated with saturated methanolic ammonia containing
a catalytic amount of sodium hydride {ca. 2 mg), and the mixture is stirred at room temperature overnight. The solvent is removed in vacuo, and the residue is chromatographed on a silica gel column using chloroform-methanol (95:5) as the eluent. Methyl 5-(2,4;3,5-di-O-benzylidene-D-hexityl)nicotinamide is obtained as a mixture of altro and allo epimers (13 and 14, R = H, R5 = CONH2, W6 = N, W5 = W7 = W8 = CH), as a form, 185 mg (87%). Η NMR (Me2SO-d5): δ 3.5-4.3 (5H, m, H-2',3',4',5',5"), 5.00 (IH, m, H-1'), 5.64 5.76, 5.77, 5.89 (2H, 4s, benzylidene -CH<), 7.39 (10H, s, phenyl), 7.50, 8.21 (4H, 2 broad s, CONH2), 8.29, 8.68, 8.95 (3H, 3m, pyridine).
By following the same procedure but using the corresponding methyl esters, the following carboxamides are prepared:
6-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinamide, 2-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinamide, 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinamide,
5-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinamide, 6-(2,4;3,5-Di-O-benzylidene-D-hexityl)picolinamide, 2-(2,4;3,5-di-O-benzylidene-D-hexityl)isonicotinamide, and 3-(2,4;3,5-di-O-benzylidene-D-hexityl)isonicotinamide. The L-isomers are also prepared in a similar manner by starting from the corresponding L-intermediates.
Example 4
5-(2,4;3,5-Di-0-benzylidene-l-0-mesyl-D-hexityl)-3-bromόpyridine (13 and 14, R = Ms, R5 = Br, W6 = N, W5= W7 = WS = CH).
An altro/allo mixture of 5-(2,4;3,5-di-O-benzylidene-D-hexityl)-3-bromopyridine
(226 mg, 0.47 mmol) is dissolved in pyridine (10 μL) and treated at 0 °C with mesyl chloride (72 μL, 0.93 mmol). The mixture is stirred at room temperature for 20 hours, and then concentrated in vacuo. The residue is dissolved in ethyl acetate (20 mL) and
the solution is washed successively with equal volumes of water, IN hydrochloric acid, brine, saturated sodium bicarbonate solution, and dried over sodium sulfate. After condensation of the solution to dryness, the residue is chromatographed on a silica gel column using n-hexane-ethyl acetate (3:7) as the eluent. 5-(2,4,3,5-Di-O-benzylidene-l- O-mesyl-D-hexityl)-3-bromopyridine as an epimeric altro/allo mixture is obtained as microcrystals, 223 mg (91%), mp 125-134 °C. Η NMR (CDC13): δ 2.93, 2.95 (3H, 2s, Ms), 3.7-4.5 (5H, m, H-2',3',4',5',5"), 5.51, 5.66, 5.79 (2H, 3s, benzylidene -CH<), 5.90 (IH, m, H-1'), 7.40 (10H, s, phenyl), 8.0 (IH, m, H-2), 8.7 (2H, m, H-4,6).
By following the same procedure but using the corresponding altro/allo mixture of (2,4;3,5-di-O-benzylidene-D-hexityl)pyridines as the starting materials, the following mesylates are also prepared:
4-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-2-bromopyridine,
3-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-2-bromopyridine,
5-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-hexityl)-2-bromopyridine,
6-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-2-bromopyridine,
6-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-hexityl)-3-bromopyridine,
4-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexi tyl)-3 -bromopyridine,
2-(2,4;3,5-Di-O-benzylidene 1 -O-mesyl-D-hexityl)-3 -bromopyridine,
2-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-4-bromopyridine,
3-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-4-bromopyridine,
4-(2,4;3,5-Di-O-benzyliden& l-O-mesyl-D-hexityl)-2-chloropyridine,
3-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-hexityl)-2-chloropyridine,
5-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-2-chloropyridine,
6-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-hexityl)-2-chloropyridine,
6-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-3 -chloropyridine,
5-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-3 -chloropyridine,
4-(2,4;3,5-Di-O-benzylidene 1 -O-mesyl-D-hexityl)-3 -chloropyridine,
2-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-3 -chloropyridine,
2-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-hexityl)-4-chloropyridine,
3-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-4-chloropyridine,
4-(2,4;3,5-Di-O-benzyliden& l-O-mesyl-D-hexityl)-2-iodopyridine,
3-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-hexityl)-2-iodopyridine,
5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-2-iodopyridine, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-2-iodopyridine, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-3-iodopyridine, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-3-iodopyridine, 4-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-3-iodopyridine, 2-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-3-iodopyridine, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-4-iodopyridine, 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-4-iodopyridine, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-2-cyanopyridine, 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-2-cyanopyridine, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-2-cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-2-cyanopyridine, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-3-cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-3-cyanopyridine, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-3-cyanopyridine, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-3-cyanopyridine, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)-4-cyanopyridine, 3-(2,4;3 ,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)-4-cyanopyridine, Methyl 6-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-hexityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-hexityl)nicotinate, Methyl 2-(2,4;3,5-di-O-benzylidene- 1 -O-mesyl-D-hexityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-hexityl)picolinate, Methyl 3-(2,4;3,5^di-O-benzylidene-l-O-mesyl-D-hexityl)picolinate, Methyl 5-(2,4;3,5-di-O-benzylidene- 1 -O-mesyl-D-hexityl)picolinate, Methyl 6-(2,4;3,5-di-O-benzylidene- 1 -O-mesyl-D-hexityl)picolinate, Methyl 2-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-hexityl)isonicotinate, Methyl 3-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-hexityl)isonicotinate, 2-(2,4;3 ,5-Di-O-benzylidene- 1 -O-mesyl-D-hexityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)picohnamide, 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)picolinamide, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)picolinamide, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)picolinamide, 2-(2,4;3,5-Di-O-benzylidene-l- -mesyl-D-hexityl)isonicotinamide, and
3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-hexityl)isonicotinamide.
By following the same procedure but using tosyl chloride, triflyl chloride, triflyl anhydride or tresyl chloride instead of mesyl chloride, the corresponding sulfonylates of the above mesylates are also prepared.
In a similar manner, the corresponding L-derivatives are prepared.
Example 5
5-(β-D-Ribofuranosyl)nicotinamide (II, R5 = CONH2, W6 = N, WS = W7 = W8 = CH) and 5-(a-D-ribofuranosyl)nicotinamide (17, R5 = CONH2, W6 = N, W5 = W7 = W8 = CH).
An altro/allo mixture of 5-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-hexityl)- nicotinamide (48 mg, 0.19 nM) is dissolved in a mixture of trifluoroacetic acid and chloroform (4:1 v/v), and the mixture is stirred for 15 minutes at room temperature.
Water (8 mL) is added and the aqueous layer is washed five times with ethyl ether (equal volume each). After evaporation of the aqueous solution, the residue is chromatographed on a silica gel column using chloroform-methanol (9:1 v/v) as the eluent. 5-β-D-Ribofuranosyl)nicotinamide [II, R5 = CONH2, W6 = N, W5 = W7 = W8 =
CH) is eluted first from the column, and obtained as a powder. !H NMR (Me2SO-d6): δ
8.92 (IH, d, H-4, spacing 1.92 Hz), 8.70 (IH, d, H-6, spacing 1.92 Hz), 8.16 (IH, m, H-
2), 4.68 (IH, d, H-1', Jr,2' = 7.4 Hz), 3.06-3.16 (5H, m, H-2',3',4',5',5"). 5-(α-D-
Ribofuranosyl)nicotinamide [17, R5 = CONH2, W6 = N, W5 = W7 = W8 = CH) is eluted next from the column, and crystallized from methanol, mp 210-212 °C. 1H NMR
(Me2SO-ds): δ 8.89 (IH, bs, H-2), 8.59 (IH, bs, H-6), 8.14 (IH, bs, H-4), 5.08 (IH, bs,
H-1'), 3.17-4.12 (5H, m, H-2',3',4',5',5").
By following the same procedure but using the corresponding altro/allo mixture of (2,4;3,5-di-O-benzylidene-D-hexityl)pyridines as the starting materials, the following pyridine C-nucleosides are also prepared:
3-(β-D-ribofuranosyl)-2-bromopyridine, 4-(β-D-ribofuranosyl)-2-bromopyridine, 5-(β- D-ribofur--nosyl)-2-bromoρyridine, 6-(β-D-ribofuranosyl)-2-bromopyridine, 6-(β-D-
ribo-mranosyl)-3 -bromopyridine, 4-(β-D-ribofuranosyl)-3-bromopyridine, 2-(β-D-ribo- furanosyl)-3 -bromopyridine, 2-(β-D-ribofuranosyl)-4-bromopyridine, 3-(β-D-ribo- furanosyl)-4-bromopyridine, 4-(β-D-ribofuranosyl)-2-chloropyridine, 3 -(β-D-ribo- furanosyl)-2-chloropyridine, 5-(β-D-ribo-furanosyl)-2-chloropyridine, 6-(β-D-ribo- furanosyl)-2-chloropyridine, 6-(β-D-ribofuranosyl)-3-chloropyridine, 5-(β-D- ribofuranosyl)-3 -chloropyridine, 4-(β-D-ribofuranosyl)-3-chloro-pyridine, 2-(β-D- ribofuranosyl)-3-chloro-pyridine, 2-(β-D-ribofuranosyl)-4-chloropyridine, 3-(β-D- ribofuranosyl)-4-chloropyridine, 4-(β-D-ribofuranosyl)-2-iodopyridine, 3-(β-D-ribo- furanosyl)-2-iodopyridine, 5-(β-D-ribo-furanosyl)-2-iodopyridine, 6-(β-D- ribofuranosyl)-2-iodopyridine, 6-(β-D-ribofuranosyl)-3-iodopyridine, 5-(β-D- ribofuranosyl)-3-iodopyridine, 4-(β-D-ribofuranosyl)-3-iodopyridine, 2-(β-D- ribofuranosyl)-3-iodopyridine, 2-(β-D-ribo-furanosyl)-4-iodopyridine, 3-(β-D-ribo- furanosyl)-4-iodopyridine, 4-(β-D-ribofuranosyl)-2-cyanopyridme, 3-(β-D- ribofuranosyl)-2-cyanopyridine, 5-(β-D-ribofuranosyl)-2-cyano-pyridine, 6-(β-D- ribofuranosyl)-2-cyano-pyridine, 5-(β-D-ribofuranosyl)-3-cyanopyridine, 6-(β-D- ribofuranosyl)-3-cyanoρyridine, 4-(β-D-ribofuranosyl)-3-cyanopyridine, 2-(β-D-ribo- furanosyl)-3-cyanopyridine, 2-(β-D-ribo-furanosyl)-4-cyanopyridine, 3-(β-D- ribofuranosyl)-4-cyanopyridine, methyl 6-(β-D-ribo-furanosyl)nicotinate, methyl 4-(β- D-ribofur-mosyl)nicotinate, methyl 2-(β-D-ribo-furanosyl)nicotinate, methyl 4-(β-D- ribofuranosyl)picolinate, methyl 3-(β-D-ribo-furanosyl)picolinate, methyl 5-(β-D- ribofuranosyl)picolinate, methyl 6-(β-D-ribo-furanosyl)picolinate, methyl 2-(β-D- ribofuranosyl)isonicotinate, methyl 3-(β-D-ribo-furanosyl)-isonicotinate, methyl 6-(β-D- ribofuranosyl)nicotinate, methyl 4-(β-D-ribo-furanosyl)nicotinate, 2-(β-D- ribofuranosyl)nicotinamide, 4-(β-D-ribofuranosyl)-picolinamide, 3-(β-D-ribo- furanosyl)picolinamide, 5-(β-D-ribofuranosyl)picolinamide, 6-(β-D-ribofuranosyl)- picolinamide, 2-(β-D-ribofuranosyl)isonicotinamide, 3-(β-D-ribo- furanosyl)isonicotinamide, 4-(α-D-ribofuranosyl)-2-bromopyridine, 3-(α-D- ribofuranosyl)-2-bromopyridine, 5-( -D-ribo-furanosyl)-2-bromopyridine, 6-(α-D- ribofuranosyl)-2-bromo-ρyridine, 6-(α-D-ribofuranosyl)-3-bromopyridine, 4-(α-D- ribofuranosyl)-3-bromopyridine, 2-(α-D-ribofuranosyl)-3-bromo-pyridine, 2-(α-D- ribofuranosyl)-4-bromopyridine, 3-(α-D-ribofuranosyl)-4-bromopyridine, 4-(α-D-
ribofuranosyl)-2-chloropyridine, 3-(α-D-ribo-furanosyl)-2-chloropyridine, 5-(α-D-ribo- furanosyl)-2-chloropyridine, 6-(α-D-ribo-furanosyl)-2-chloropyridine, 6-(α-D- ribofuranosyl)-3-chloropyridine, 5-(α-D-ribo-furanosyl)-3-chloropyridine, 4-( -D- ribofuranosyl)-3-chloro-pyridine, 2-(α-D-ribo-furanosyl)-3-chloropyridine, 2-(α-D- ribofuranosyl)-4-chloropyridine, 3-(α-D-ribo-furanosyl)-4-chloropyridine, 4-(α-D- ribofuranosyl)-2-iodopyridine, 3-(α-D-ribo-ftιranosyl)-2-iodopyridine, 5-(α-D- ribofuranosyl)-2-iodopyridine, 6-( -D-ribofuranosyl)-2-iodo-pyridine, 6-(α-D- ribofuranosyl)-3-iodopyridine, 5-(α-D-ribofuranosyl)-3-iodopyridine, 4-(α-D- ribofuranosyl)-3 -iodopyridine, 2-(α-D-ribofuranosyl)-3-iodopyridine, 2-(α-D-ribo- furanosyl)-4-iodopyridine, 3-(α-D-ribofuranosyl)-4-iodopyridine, 4-(α-D-ribofuranosyl)-
2-cyanopyridine, 3 -(α-D-ribofuranosyl)-2-cyanopyridine, 5 -(α-D-ribofuranosyl)-2- cyano-pyridine, 6-(α-D-ribofuranosyl)-2-cyanopyridine, 5-(α-D-ribofuranosyl)-3- cyanopyridine, 6-( -D-ribofuranosyl)-3 -cyanopyridine, 4-( -D-ribofuranosyl)-3- cyanopyridine,2-(α-D-ribofuranosyl)-3-cyanopyridine, 2-(α-D-ribofuranosyl)-4- cyanopyridine, 3-( -D-ribo-furanosyl)-4-cyanopyridine, methyl 6-(α-D- ribofuranosyl)nicotinate, methyl 4-(α-D-ribo-furanosyl)nicotinate, methyl 2-(α-D- ribofuranosyl)nicotinate, methyl 4-(α-D-ribo-furanosyl)picolinate, methyl 3-(α-D- ribofuranosyl)picolinate, methyl 5-(α-D-ribo-furanosyl)picolinate, methyl 6-(α-D- ribofuranosyl)picolinate, methyl 2-(α-D-ribo-furanosyl)isonicotinate, methyl 3-(α-D- ribo-furanosyl)isonicotinate, methyl 6-( -D-ribo-furanosyl)nicotinate, methyl 4-( -D- ribofuranosyl)nicotinate, 2-(α-D-ribofuranosyl)-nicotinamide, 4-(α-D-ribofuranosyl)- picolinamide, 3-(α-D-ribofuranosyl)picolinamide, 5-(α-D-ribofuranosyl)picolinamide, 6- (α-D-ribofuranosyl)picolinamide, 2-( -D-ribo-furanosyl)isonicotinamide, and 3-(α-D- ribo-furanosyl)isonicotinamide. By following the same procedures but using the corresponding altro/allo mixtures of (2,4;3,5-di-O-benzylidene-L-hexityl)pyridines as the starting material, the L- nucleoside counterparts of the above C-nucleosides are also prepared.
Example 6
5-(β-D-Ribofuranosyl)nicotinamide (II, R5=CONH2, W6=N_ W5=W7=W8=CH) and 5-(a- D-ribofuranosyl)nicotinamide (17, R5=CONH2, Wδ=N, W5=W7=W8=CH) - an alternative synthesis.
A solution of an altro/allo isomeric mixture of 5-(2,4;3,5-di-O-benzylidene-D- hexityl)-3-cyanopyridine (80 mg, 0.19 mmol) in a mixture of water and methanol (10 mL, 1:1) is refluxed for 1.5 hours with Amberlite 400 (OH") (3 g). The resin is removed by filtration and the filtrate is concentrated to dryness in vacuo. The residue is purified by silica gel column chromatography using chloroform-methanol (95:5 v/v) as the eluent. 5-(2,4;3,5-di-O-benzylidene-D-hexityl)-nicotinamide is obtained as an altro/allo mixture, which is identical with an authentic sample prepared according to the procedure as described in Example 3.
By following the procedure of Example 6 but using the corresponding cyanopyrimidine derivatives, the following carboxamides are also synthesized: 4-(2,4;3,5-di-O-benzylidene-D-hexityl)picolinamide, 3-(2,4;3,5-di-O-benzylidene-D- hexityl)picolinamide, 5-(2,4;3,5-di-O-benzylidene-D-hexityl)picolinamide, 6-(2,4;3,5-di- O-benzylidene-D-hexityl)picolinamide, 6-(2,4;3,5-Di-O-benzylidene-D-hexityι)- nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-D-hexityl)nicotinamide, 2-(2,4;3,5-Di-O- benzylidene-D-hexityl)nicotinamide, 2-(2,4;3,5-Di-O-benzylidene-D- hexityl)isonicotinamide, and 3-(2,4;3,5-Di-O-benzylidene-D-hexityl)isonicotinamide.
These carboxamides synthesized by the procedure described in Example 6 are identical with the corresponding samples prepared by following the procedure of Example 3.
Example 7
Separation of altro- and allo-isomers.
A crude altro/allo isomeric mixture of 6-(2,4;3,5-di-O-benzylidene-D-hexityl)-2- bromopyridine prepared by condensation of 2,6-dibromopyridine (2.18 g, 9.20 mmol) and 2,4,3,5-di-O-benzylidene-D-aldehydo-ribose (1.0 g, 3.06 mmol) according to the procedure of Example 1 is placed on a silica gel column, which is washed with n- hexane-ethyl acetate (94:6). 6-(2,4,3,5-Di-O-benzylidene-D-altrityl)-2-bromopyridine (342 mg, 23%) is eluted first. The column is then washed with ra-hexane-ethyl acetate (92:8) solvent system, which elutes 6-(2,4,3,5-di-O-benzylidene-D-allityl)-2- bromopyridine (282 mg, 19%). Both isomers are obtained as foams.
Η NMR for the altrityl isomer (CDC13): δ 7.55-7.05 (13H, m, aromatic H), 5.77, 5.49 (2H, 2s, benzylidene -CH<), 5.14 (IH, q, collapsed to d on addition of D2O, H-1', Jr>2> = 3.02 Hz), 4.40 (2H, m, H-2',3'), 3.92 (3H, m, H-4',5',5").
]H NMR for the allityl isomer (CDCI3): δ 7.49-7.24 (13H, m, aromatic H), 5.66, (2H, 2s, benzylidene -CH<), 5.0 (IH, broad s, H-1'), 4.32 (2H, m, H-2',3'), 3.97 (3H, m, H-
4',5',5").
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-D-hexityl)pyridines, the following derivatives are obtained:
4-(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-bromopyridine, 4-(2,4;3,5-Di-O-benzylidene-D-allityl)-2-bromopyridine,
3-(2,4;355-Di-O-benzylidene-D-altrityl)-2-bromopyridine,
3-(2,4;3,5-Di-O-benzylidene-D-allityl)-2-bromopyridine,
3-(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-bromopyridine,
3-(2,4;3,5-Di-O-benzylidene-D-allityl)-2-bromopyridine, 6-(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-bromopyridine,
6-(2,4;3,5-Di-O-benzylidene-D-allityl)-3-bromopyridine,
5-(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-bromopyridine,
5-(2,4;3,5-Di-O-benzylidene-D-allityl)-3-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-bromopyridine,
-(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-bromopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2 -chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-chloropyridine, -(2,4;3 ,5-Di-O-benzylidene-D-allityl)-3 -chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-chloropyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-iodopyridine,
-(2,4;3,5-Di-O-benzylidene-D-allityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-iodopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzyhdene-D-altrityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-cyanopyridine3 -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzyUdene-D-altrityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-3-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-cyanopyridine, -(2,4;3,5-Di-O-benzylidene-D-altrityl)-4-cyanopyridine, and -(2,4;3,5-Di-O-benzylidene-D-allityl)-4-cyanopyridine.
Example 8
Methyl 6-(2,4;3,5-di-0-benzylidene-D-altrityl)picolinate (13, R-H, R5=C02CH3, W6=N, W5 =W7=W8=CH).
A solution of 6-(2,4;3,5-di-O-benzylidene-D-altrityl)-2-bromopyridine (200 mg, 0.43 mmol) in hexamethylphosphoric triamide (0.25 mL) and ethyl ether (5 mL) is treated at -78 °C with butyllithium (2 mL of 2.5 M in «-hexane). After stirring for 15 minutes at -78 °C, excess solic carbon dioxide is added and the mixture is allowed to warm to room temperature while stirring. The mixture is neutralized with IN hydrochloric acid, and then the product is extracted with ethyl ether (15 mL x 2). The extracts are combined, washed with brine (20 mL x 3), dried over sodium sulfate, filtered, and the filtrate treated with ethereal solution of diazomethane. Excess diazomethane is decomposed by addition of acetic acid, and then the mixture is concentrated in vacuo. The residue is chromatographed on a silica gel column using n- hexane-ethyl acetate (75:25). Methyl 6-(2,4;3,5-di-O-benzylidene-D-atrityl)picolinate (122 mg, 64%) is obtained as colorless crystals, mp 176-179 °C (after recrystalhzation from ethyl ether). 1H NMR (CDC13): δ 8.07-7.31 (13H, m, aromatic), 5.64, 5.67 (2H, 2s, benzylidene -CH<), 5.25 (IH, broad s, H-1'), 4.43-3.95 (5H, H-2',3',4',5',5"), 3.95 (3H, s, CH3 ester).
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-D-altrityl)bromopyrimidines as the starting materials, the following methyl esters are prepared:
Methyl 6-(2,4;3,5-di-O-benzylidene-D-altrityl)nicotinate, Methyl 5-(2,4;3,5-di-O- benzylidene-D-altrityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-D- altrityfjnicotinate, Methyl 2-(2,4;3,5-di-O-benzylidene-D-altrityl)nicotinate, Methyl 4- (2,4;3,5-di-O-benzylidene-D-altrityl)-picolinate, Methyl 3-(2,4;3,5-di-O-benzylidene-D- altrityl)picolinate, Methyl 5-(2,4;3,5-di-O-benzylidene-D-altrityl)picolinate, Methyl 2- (2,4;3,5-di-O-benzylidene-D-altrityl)isonicotinate and Methyl 3-(2,4;3,5-di-O- benzylidene-D-altrityl)isonicotinate.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-D-allityl)bromopyrimidines as the starting materials, the following methyl esters are prepared:
Methyl 6-(2,4;3,5-di-O-benzylidene-D-allityl)nicotinate, Methyl 5-(2,4;3,5-di-O- benzylidene-D-allityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-D- allityl)nicotinate, Methyl 2-(2,4;3,5-di-O-benzylidene-D-allityl)nicotinate, Methyl 4- (2,4;3,5-di-0-benzylidene-D-allityl)picolinate, Methyl 3-(2,4;3,5-di-O-benzylidene-D- allityl)picolinate, Methyl 5-(2,4;3,5-di-O-benzylidene-D-allityl)picolinate, Methyl 6- (2,4;3,5-di-0-benzylidene-D-allityl)picolinate, Methyl 2-(2,4;3,5-di-O-benzylidene-D- allityl)isonicotinate and Methyl 3-(2,4;3,5-di-O-benzylidene-D-allityl)-iso-nicotinate.
Example 9
6-(2,4;3,5-Di-0-benzylidene-D-allityl)picolinamide (14, R = H, R5 = CONH2, W6 = N, W5 = W7 = W8 = CH).
Methyl 6-(2,4;3,5-di-O-benzylidene-D-allityl)picolinate (75 mg, 0.16 mmol) is dissolved in a 4:1 mixture of methanol and ammonia containing a catalytic amount of sodium hydride (ca. 2 mg). The solution is stirred at room temperature for 20 hours, and then is concentrated to dryness in vacuo. The residue is purified by chromatography on a silica gel column. 6-(2,4;3,5-Di-O-benzylidene-D-allityl)picolinamide is obtained as colorless crystals, 65 mg (89%), mp 201-203 °C (recrystalhzation from «-hexane- methanol). 1H ΝMR (CDC13): δ 8.07-7.11 (13H, m, aromatic), 5.78, 5.51 (2H, 2s, benzylidene -CH-Ph), 5.19 (IH, q, H-1', collapsed to a doublet upon addition of D2O, Jr,2' = 3.29 Hz), 4.40 (2H, m, H-2',3'), 3.91 (3H, m, H-4',5',5").
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzilidene-L-altrityl)bromopyridines as the starting materials, the L-counterparts of the above compounds are prepared.
By following the same procedure but using the corresponding methyl esters, the following carboxamides are prepared:
6-(2,4;3,5-Di-O-benzylidene-D-allityl)nicotinamide, 5-(2,4;3,5-Di-O-benzylidene-D- allityl)-nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-D-allityl)nicotinamide, 2-(2,4;3,5-Di- O-benzylidene-D-allityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-D- allityl)picolinamide, 3-(2,4;3,5-Di-O-benzylidene-D-allityl)picolinamide, 5-(2,4;3,5-Di- O-benzylidene-D-allityl)-picolinamide, 6-(2,4;3,5-Di-O-benzylidene-D- allityl)picolinamide, 2-(2,4;3,5-Di-O-benzylidene-D-allityl)-iso-nicotinamide, 3-(2,4;3,5- Di-O-benzylidene-D-allityl)-iso-nicotinamide, 6-(2,4;3 ,5 -Di-O-benzyl-idene-D- altrityι)nicotinamide, 5-(2,4;3,5-Di-O-benzylidene-D-altrityl)nicotinamide, 4-(2,4;3,5- Di-O-benzylidene-D-altrityl)nicotinamide, 2-(2,4;3,5-Di-O-benzylidene-D- altrityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-D-altrityl)picolinamide, 3-(2,4;3,5-
Di-O-benzylidene-D-altrityl)-picolinamide, 5-(2,4;3,5-di-O-benzylidene-D- altrityl)picolinamide, 6-(2,4;3,5-di-O-benzylidene-D-altrityl)picolinamide, 2-(2,4;3,5-di- O-benzylidene-D-altrityl)isonicotinamide and 3-(2,4;3,5-di-O-benzylidene-D- altrityl)isonicotinamide. By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-L-allityl)bromopyridines as the starting materials, the L-counterparts of the above compounds are prepared.
Example 10
6-(2,4;3,5-Di-0-benzylidene-l-0-mesyl-D-altrityl)picolinamide (15, R=Ms, R5=CONH2, W6=N, W5=W7=W8=CH).
A solution of 6-(2,4;3,5-di-O-benzylidene-D-altrityl)picolinamide (50 mg, 0.11 mmol), triethylamine (150 μL, 1.08 mmol) and 4-dimethylaminopyridine (ca. 3 mg) in methylene chloride (4 mL) is treated at room temperature with mesyl chloride (40 μL, 0.52 mmol). The mixture is stirred for 30 minutes at room temperature, and then concentrated in vacuo to dryness. The residue is chromatographed on a silica gel column using methylene chloride-methanol (98:2) as the eluent. 6-(2,4;3,5-Di-O-benzylidene-l- O-mesyl-D-altrityl)picolinamide (49 mg, 83 %) is obtained after recrystalhzation from n- hexane-ethyl ether, mp 109-110 °C. 1H NMR (CDC13): δ 8.20-7.34 (13H, m, aromatic),
6.03 (IH, d, H-1', Ji',2. = 2.47 Hz), 5.68, 5.61 (2H, 2s, benzylidene -CH<), 4.48-3.94 (5H, H-2',3',4',5',5"), 3.02 (3H, s, mesyl CH3).
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-D-altrityl)pyridines, the following mesyl derivatives are prepared: 4-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-altrityl)-2-bromopyridine,
3-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-altrityl)-2-bromopyridine, 5-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-2-bromoρyridine, 6-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-altrityl)-2-bromoρyridine, 6-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-3-bromopyridine, 4-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-altrityl)-3 -bromopyridine,
2-(2,4;3 ,5-Di-O-benzylidene' l-O-mesyl-D-altrityl)-3-brornopyridine, 2-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-altrityl)-4-bromopyridine, 3-(2,4;3,5-Di-O-benzylidene' l-O-mesyl-D-altrityl)-4-bromopyridine, 4-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-2-chloropyridine, 3-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-2-chloropyridine,
5-(2,4;3,5-Di-O-benzylidene 1 -O-mesyl-D-altrityl)-2-chloropyridine, 6-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-altrityl)-2-chloropyridine, 6-(2,4;3,5-Di-O-benzylidene 1 -O-mesyl-D-altrityl)-3 -chloropyridine, 5-(2,4;3,5-Di-O-benzyliden& l-O-mesyl-D-altrityl)-3-chloropyridine, 4-(2,4;3,5-Di-O-benzylidene' 1 -O-mesyl-D-altrityl)-3 -chloropyridine,
2-(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-altrityl)-3 -chloropyridine, 2-(2,4;3,5-Di-O-benzylidene' l-O-mesyl-D-altrityl)-4-chloropyridine, 3-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-4-chloropyridine, 4-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-2-iodopyridine, 3-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-2-iodopyridine,
5-(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-2-iodopyridine, 6-(2,4;3,5-Di-O-benzylidene l-O-mesyl-D-altrityl)-2-iodopyridine, -(2,4;3,5-Di-O-benzyliden& l-O-mesyl-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzyliden& l-O-mesyl-D-altrityl)-3-iodopyridine, -(2,4;3,5-Di-O-benzylidene- l-O-mesyl-D-altrityl)-4-iodopyridine,
3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-4-iodopyridine, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-2-cyanopyridine, 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-2 -cyanopyridine, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-2-cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-2-cyanopyridine, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-3-cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-3-cyanopyridine, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-3-cyanopyridine, 2-(2!4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-3-cyanopyridine, 2-(2,4;3 ,5-Di-O-benzylidene- 1 -O-mesyl-D-altrityl)-4-cyanopyridine, 3-(2!4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)-4-cyanopyridine, Methyl 6-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)nicotinate:, Methyl 4-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)nicotinate, Methyl 2-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)ρicolinate, Methyl 3-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)picolinate, Methyl 5-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)picolinate, Methyl 6-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)picolinate, Methyl 2-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)isonicotinate, Methyl 3-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-altrityl)isonicotinate, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)picolinamide, 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)picolinamide, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)picolinamide, 6-(2,4;3 ,5-Di-O-benzylidene-l -O-mesyl-D-altrityl)picolinamide, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)isonicotinamide, and 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-altrityl)isonicotinamide.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-L-allityl)bromoρyridines as the starting materials, the L-counterparts of the above compounds are prepared.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-D-allityl)pyridines, the following compounds are synthesized:
-(2,4;3,5-Di-O-benzyliden& 1 -O-mesyl-D-allityl) ■2-bromopyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) •2-bromopyridine, -(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-allityl) ■2-bromopyridine, -(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-allityl) •2-bromopyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) •3 -bromopyridine, -(2,4;3 ,5-Di-O-benzylidene' 1-O-mesyl-D-allityl) ■3 -bromopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) ■3 -bromopyridine, -(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-allityl)' •4-bromopyridine, -(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-allityl) '-4-bromopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -2-chloropyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -2-chloropyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -2-chloropyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) -2-chloropyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) -3 -chloropyridine, -(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-allityl) -3 -chloropyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -3 -chloropyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) -3 -chloropyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -4-chloropyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -4-chloropyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl)' -2-iodopyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) -2-iodopyridine, -(2,4;3,5-Di-O-benzylidene' 1-O-mesyl-D-allityl) -2-iodopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -2-iodopyridine, -(2,4;3,5-Di-O-benzylidene' 1-O-mesyl-D-allityl) -3-iodopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -3-iodopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -3-iodopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -3-iodopyridine, -(2,4;3,5-Di-O-benzylidene 1-O-mesyl-D-allityl) -4-iodopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -4-iodopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene- 1-O-mesyl-D-allityl) -2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene' 1-O-mesyl-D-allityl) -2-cyanopyridine, -(2,4;3,5-Di-O-benzylidene- 1 -O-mesyl-D-alhtyl) -2-cyanopyridine,
5 -(2,4 ; 3 , 5 -Di-O-benzylidene- 1 -O-mesyl-D-allityl)-3 -cyanopyridine, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)-3-cyanopyridine, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)-3-cyanopyridine, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)-3-cyanopyridine, 2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)-4-cyanopyridine,
3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)-4-cyanopyridine, Methyl 6-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)nicotinate, Methyl 2-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)nicotinate, Methyl 4-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)picolinate,
Methyl 3-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)picolinate, Methyl 5-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)picolinate, Methyl 6-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)picolinate, Methyl 2-(2,4;3 ,5-di-O-benzylidene- 1 -O-mesyl-D-allityl)isonicotinate, Methyl 3-(2,4;3,5-di-O-benzylidene-l-O-mesyl-D-allityl)isonicotinate,
2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)nicotinamide, 4-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)picolinamide, 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)picolinamide, 5-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)picolinamide, 6-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)picolinamide,
2-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)isonicotinamide, and 3-(2,4;3,5-Di-O-benzylidene-l-O-mesyl-D-allityl)isonicotinamide.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-L-allityl)pyridines as the starting material, the L-counterparts of the above compounds are prepared.
Example 11
5-(β-D-Ribofuranosyl)-3-cyanopyridine ([II], R5 = CN, W6 = N, W5 = W7 = W8 = CH).
5-(2,4;3,5-Di-O-benzyhdene-l-O-mesyl-D-altrityl)-3-cyanopyridine (28 mg, 0.06 mmol) is dissolved in a 4:1 mixture of trifluoroacetic acid and chloroform (4 mL). After
stirring for 15 minutes at room temperature, the reaction is quenched by addition of water (10 mL). The aqueous layer is separated, extracted five times with ethyl ether (10 mL each), and then concentrated in vacuo. The residue is chromatographed on a silica gel column using methylene chloride-methanol as the eluent. 5-(β-D-Ribofuranosyl)-3- cyanopyridine (8 mg, 57%) is obtained as colorless crystals, mp 169-171 °C (after recrystalhzation from ethanol). !H NMR (Me2SO-d6): δ 8.93 (IH, d, H-2, spacing 1.93 Hz), 8.86 (IH, d, H-6, spacing 1.93 Hz), 8.31 (IH, m, H-4), 4.93 (IH, d, H-1', Jr>2. - 7.41 Hz), 3.99-3.50 (5H, m, H-2',3',4',5',5").
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene- 1 -O-mesyl-D-altrityl)pyridines, all the (β-D-ribofuranosyl)pyrimidine C- nucleosides synthesized according to the procedure of Example 5 are prepared, and their spectral properties are identical to the corresponding β-C-nucleosides.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-l-O-mesyl-D-allityl)pyridines, all the (α-D-ribofuranosyl)pyrimidine C- nucleosides synthesized according to the procedure of Example 5 are obtained, and their spectral properties are identical to the corresponding α-C-nucleosides.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-l-O-mesyl-y-altrityl)pyridines, all the (β-l-ribofuranosyl)pyrimidine C- nucleosides synthesized according to the procedure of Example 5 are prepared, and their spectral properties are identical to the corresponding β-C-nucleosides.
By following the same procedure but using the corresponding (2,4;3,5-di-O- benzylidene-l-O-mesyl-y-allityl)pyridines, all the ( -b-ribofuranosyl)ρyrimidine C- nucleosides synthesized according to the procedure of Example 5 are obtained, and their spectral properties are identical to the corresponding α-C-nucleosides.
Example 12
Pl-[7-Hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-t^-(2 ',3 '-0-iso- propylideneadenosine-5 '-yl)methylene-bis(phosphonate) ([I], Rι,R2 = 0-C(CHi)2-0, R3 = R4 = H, Y = NH2, Z = H, X= CH2, R = [V]).
To a solution of 2',3'-O-isopropylideneadenosine-5'-methylenebis(phosphonate)
([I], R, = R2 = OH, R3 = RA = H, Y = NH2, Z = H, X = CH2, R = H) (700 mg, 1 mmol) in pyridine (4.0 mL) is added diisopropylcarbodiimide (7.8 L, 5 mmol), and the mixture is shaken at room temperature. When three characteristic multi-signal resonances appear at -0.5-2.0 ppm, at 6.0-8.0 ppm and at 12.8-17.6 ppm, 6-(2-hydroxyethyl)-7-hydroxy-5- methoxy-4-methylphthalan-l-one (262 mg, 1.1 mmol) is added and the reaction is heated at 55-60 °C for 24 hours. The reaction is quenched by adding water (1 mL) and triethylamme (0.5 mL) when the 31P NMR spectrum of the reaction mixture exhibits two broad signals at 8 ppm and 25 ppm. The mixture is kept at 80-85 °C for 30 hours. HPLC purification on a Dynamax-300A C18-82-243-C column with a flow rate of 20 mL/min of 0.05 M triethylammonium bicarbonate (TEAB) followed by a linear gradient of 0.05 M TEAB-aq. Acetonitrile (70%) affords P1-[7-hydroxy-5-methoxy-4- methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O-isopropylideneadenosine-5'- yl)methylene-bis-(phosphonate) ([I], Rι,R2 = O-C(CH3)2-O, R3 = R4 = H, Y = NH2, Z = H, X = CH2, R = [V]), 60 mg (32%) as the triethylammonium salt. H NMR (D2O): δ 1.24 (18H, t, (CH3CH2)3N), —
By following the same procedure but using the corresponding 2',3'-O-protected nucleosides, the following compounds are synthesized:
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2,'3'-O- isoproρylideneinosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropyhdeneguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isoρropylidenenebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isoproρylidenexanthosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-6-thioinosine-5-yl)methylenebis(phosphonate),
P'-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-6-thioguanosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l -on-6-(ethyl-2-yl)]-P2-(2',3 '-O- isopropylidene-O6-methylinosine-5-yl)methylenebis(phosphonate)s
PI-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-O6-methylguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-2-aminoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-2-fluoroadenosine-5-yl)methylenebis(phosphonate),
P1 -[7-hydroxy-5-methoxy-4-methylphthalan- 1 -on-6-(ethyl-2-yl)]-P2-(2 ' ,3 '-O- isopropylidene-2-chloroadenosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3 '-O- isopropylidene-2-bromoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-6-chloronebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-6-methylthioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-8-azaadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-8-azainosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2',3'-O- isopropylidene-8-azaguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3 '-deoxy-3 '-fluoroinosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3 '-deoxy-3 '-fluoroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P -(2'-O- acetyl-3 ' -deoxy-3 ' -fluoroguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoronebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoroxanthosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-6-thioinosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-6-thioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3 '-deoxy-3 '-fluoro-O -methylinosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-O6-methylguanosine-5-yl)methylenebis(phosphonate),
P 1-[7-hydroxy-5-methoxy-4-methylphthalan- 1 -on-6-(ethyl-2-yl)]-P2-(2 ' -O- acetyl-3 ' -deoxy-3 ' -fluoro-2-aminoadenosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-2-fluoroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-2-chloroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3 '-deoxy-3 '-fluoro-2-bromoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-6-chloronebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-6-methylthioguanosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-8-azaadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-8-azainosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(2'-O- acetyl-3'-deoxy-3'-fluoro-8-azaguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoroinosine-5-yl)methylenebis(phosphonate),
Pl-[7-hydroxy-5-methoxy-4-methylρhthalan-l -on-6-(ethyl-2-yl)]-P2-(3 ' -O- acetyl-2'-deoxy-2'-fluoroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoroguanosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoronebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoroxanthosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2 ' -deoxy-2 '-fluoro-6-thioinosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-6-thioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-O6-methylinosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3 '-O- acetyl-2'-deoxy-2'-fluoro-O6-methylguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-2-aminoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-2-fluoroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-2-chloroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-2-bromoadenosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-6-chloronebularine-5-yl)methylenebis(phosphonate)J
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-6-methylthioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-8-azaadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-8-azainosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-(3'-O- acetyl-2'-deoxy-2'-fluoro-8-azaguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenin-5'-yl]methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)hypoxanthin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanin-5'-yl]methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)purin-5'-yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)xanthine-5'- yl]methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-thiopurin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-thioguanine-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methoxylpurin-5'- yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-O0-methylguanine-5 ' - yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-2-aminoadenine-5'- yl]methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-2-fluoroadenine-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-0- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-2-chloroadenin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-2-bromoadenin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P -[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-chloropurin-5'- yl]methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methylthioguanin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-8-azaadenin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P -[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofiιranosyl)-8-azahypoxanthin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(3-O- acetyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-8-azaguanin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)adenin-5'-yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)hypoxanthin-5 ' - yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)guanin-5'-yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)purin-5'-yl]methylenebis(ρhosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)xanthine-5'-yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-6-thiopurin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-6-thioguanine-5 '- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-6-methoxylpurin-5 ' - yl)methylenebis(phosphonate), P1 -[7-hydroxy-5-methoxy-4-methylphthalan-l -on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-O6-methylguanine-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-2-aminoadenine-5'- yl]methylenebis(phosphonate),
P1 -[7-hydroxy-5-methoxy-4-methylρhthalan- 1 -on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-2-fluoroadenine-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-2-chloroadenin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-2-bromoadenin-5'- yl]methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-6-chloropurin-5 ' - yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-6-methylthioguanin-5 ' - yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-8-azaadenin-5'- yl]methylenebis(phosphonate),
P1 -[7-hydroxy-5-methoxy-4-methylphthalan- 1 -on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-8-azahypoxanthin-5'- yl]methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylρhthalan-l-on-6-(ethyl-2-yl)]-P2-[9-(2-O- acetyl-3-deoxy-3-fluoro-β-D-xylofuranosyl)-8-azaguanin-5'- yl]methylenebis(phosphonate) . P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]-
P2-(2',3'-0-isopropylidene-6-thioinosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-0-isopropylidene-6-thioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-0-isopropylidene-O6-methylinosine-5-yl)methylenebis(phosphonate),
P1 -[7-hydroxy-5-methoxy-4-methylphthalan- 1 -on-6-(3 -methylbut-2-ene-4-yl)] - P2-(2',3'-0-isopropylidene-O -methylguanosine-5-yl)methylenebis(ρhosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-O-isopropylidene-2-aminoadenosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]-
P2-(2',3'-O-isopropylidene-2-fluoroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-O-isopropylidene-2-chloroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-0-isopropylidene-2-bromoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-O-isopropylidene-6-chloronebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-O-isopropylidene-6-methylthioguanosine-5-yl)methylenebis(phosphonate), P l -[7-hydroxy-5 -methoxy-4-methylphthalan- 1 -on-6-(3 -methylbut-2-ene-4-ylϊJ -
P2-(2',3'-O-isopropylidene-8-azaadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-O-isopropylidene-8-azainosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylbut-2-ene-4-yl)]- P2-(2',3'-O-isoproρylidene-8-azaguanosine-5-yl)methylenebis(phosphonate),
P l - [7-hydroxy- 5-methoxy-4-methylphthalan- 1 -on-6-(3 -methylhex-2-ene-6-yl)] - P2-(2',3'-O-isopropylidene-6-thioinosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-meth4oxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]-
P2-(2',3'-O-isopropylidene-6-thioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-06-methylinosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-O6-methylguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-2-aminoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-2-fluoroadenosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]-
P2-(2',3'-O-isoρropylidene-2-chloroadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-2-bromoadenosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-6-chloronebularine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-6-methylthioguanosine-5-yl)methylenebis(phosphonate),
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-8-azaadenosine-5-yl)methylenebis(phosphonate), P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]-
P2-(2',3'-O-isopropylidene-8-azainosine-5-yl)methylenebis(phosphonate), and
P1-[7-hydroxy-5-methoxy-4-methylphthalan-l-on-6-(3-methylhex-2-ene-6-yl)]- P2-(2',3'-O-isopropylidene-8-azaguanosine-5-yl)methylenebis(phosphonate).
The L-nucleoside-containing isomers of the above compounds are prepared by using the corresponding 2,3-O-protected L-nucleosides.
Biological Methods
Cell culture assays were used to determine the anύ-Flaviviridae activity of unmodified or modified compounds of the formula (I) disclosed herein.
RNA isolation and quantitative RT-PCR analysis
An effective process to quantify the viral load in a host, termed real-time polymerase chain reaction ("RT-PCR") is provided. The process involves using a quenched fluorescent probe molecule which can be hybridized to viral DNA or RNA. Therefore, upon exonucleolytic degradation, a detectable fluorescent signal can be monitored. Therefore, the RT-PCR amplified DNA or RNA is detected in real time by monitoring the presence of fluorescence signals.
As one illustration of this method, in the case of BVDV in MDBK cells, in a first step, viral RNA is isolated from 140 μL of the cell culture supernatant by means of a commercially available column (Viral RNA extraction kit, QiaGen, CA). The viral RNA is then eluted from the column to yield a total volume of 60 μL, and subsequently amplified with a quantitative RT-PCR protocol using a suitable primer for the BVDV NADL strain. A quenched fluorescent probe molecule is hybridized to the BVDV DNA, which then undergoes exonucleolytic degradation resulting in a detectable fluorescent signal. Therefore, the RT-PCR amplified DNA was detected in real time by monitoring the presence of fluorescence signals. The TaqMan probe molecule (5' 6-fam-
AAATCCTCCTAACAAGCGGGTTCCAGG-tamara 3' [Sequence TD No. 7] and primers (sense: 5'-AGCCTTCAGTTTCTTGCTGATGT-3' [Sequence ID No. 8]; and antisense: 5'-TGTTGCGAAAGCACCAACAG-3' [Sequence ID No. 9]) were designed with the aid of the Primer Express software (PE-Applied Biosystems) to be complementary to the BVDV NADL NS5B region. A total of 10 μL of RNA was analyzed in a 50 μL RT-PCR mixture. Reagents and conditions used in quantitative PCR were purchased from PE-Applied Biosystems. The standard curve that was created using the undiluted inoculum virus ranged from 6000 plaque forming units (PFU) to 0.6 PFU per RT-PCR mixture. A linear range of over 4-logs was routinely obtained.
Cell / viral materials
One of the best characterized members of the Pestivirus genus is BVDV. BVDV and HCV share at least three common features, which are the following: (1) they both undergo IRES -mediated translation; (2) NS4A cofactor is required by their NS3 serine protease; and (3) they undergo similar polyprotein processing within the non-structural region, especially at the NS5A and NS5B junction site.
The BVDV replication system was used for the discovery of τi-Flaviviridae compounds. The compounds described herein are active against Pestiviruses, Hepaciviruses and/or Flaviviruses. Maldin-Darby bovine kidney (MDBK) cells were grown and maintained in a modified eagle medium (DMEM/F12; GibcoBRL), supplemented with 10% heat inactivated horse serum at 37°C in a humidified, 5% CO2, incubator.
Bovine viral diarrhea virus (BVDV), strain NADL, causes a cytopathogenic effect (CPE) after infection of these cells.
Example 13
Cytopathic Effect (CPE) Assay
MDBK-cells, grown in DMEM/F12 - 10% horse serum (HS), were isolated using standard techniques using trypsin-EDTA. Cells were seeded in a 96-well plate at 5 x 104 cells/well, with test compound (20 micromolar (μM) concentration) to give a total volume of 100 microliters (μL). After one hour, the media was removed and the cells were infected with cpBVDV (NADL) at a multiplicity of infection (MOI) of 0.02 or 0.002 in a total volume of 50 μL for 45 minutes. Thereafter, the virus was removed and the cells were washed twice with 100 μL of assay media. Finally, the infected cells were incubated in a total volume of 100 μL containing the test compound at 40 or 100 μM concentration. After 22 hours, the cell supernatant was collected by removing the cellular debris by low-speed centrifugation, and subsequently tested for the presence of virus in a quantitative manner. This assay proved problematic since MDBK cells are
sensitive to the compounds of the present invention. The results of this assay using Ribavirin are illustrated in Figure 3.
Example 14
Ttoxicity testing of candidate anti-Flaviviridae compounds
Cytotoxicity testing can be carried out according to standard methods. MDBK,
PBM, HeρG2, Huh7 and Vero cells were used. Briefly, cells are seeded in 96-well plates at various concentrations (dependent on cell type, duration of assay), typically at 5xl03 cells per well, in the presence of increasing concentrations of the test compound (0, 1, 3, 10, 33 and 100 μM). After a three day-incubation, cell viability and mitochondrial activity are measured by adding the MTS-dye (Promega), followed by a 3 hours incubation. Afterwards the plates containing the dye are read at 490 nm. Each assay was done in triplicate. Such methodologies are well described and available from the manufacturer (Promega).
In addition, the toxicity of C2-MAD was tested in Balb/c mice (six mice per group) at various concentrations (10, 30 and 60 mg/kg/day for ten days) as compared to water over a period often days. The results of this screening are illustrated in Figure 4.
Example 15
The BVDV RT-PCR quantification standard curve
The standard BVDV virus stock contained 2 x 106 PFU/ml, as determined by routine plaque assay (Mendez, E. et al. J. Virol. 1998, 72, 4737). Viral RNA was extracted from 140 μL of this inoculum material and eluted from a column using 60 μL of an elution buffer. This purified RNA material then was diluted stepwise from 10"1 to 10'5. Using the real-time RT-PCR amplification technique, 10 μL of each dilution was tested. The results of this dilution series are plotted in Figure 5, relating PFU to concentration of standard. From this experiment, it is clear that this technology allows
for reliable quantification over 4-logs of virus (from 6000 to 0.6 PFU/ input in amplification mix). The lower limit of detection in this experiment is 0.6 PFU or -0.22 log PFU. Therefore, the real-time RT-PCR quantification values of test samples below this detection limit were considered non-reliable.
Example 16
The BVDV replication cycle in MDBK cells
In order to measure the BVDV production in MDBK cells and to determine the optimal harvesting time over a certain period of time, cells were seeded at 5xl04 cells/well and infected either with MOI = 0.02 or MOI = 0.002. After infection, the inoculum was removed and the cells were washed twice with culture medium. At different time points, the cell supernatant was harvested; and, the amount of virus was measured and compared to the original inoculum and the cell wash, as shown in Figure 6. At least 2 wash-steps were needed to remove the inoculum virus. The amount of virus produced 22 hours after infection approximately equals the amount of virus used to inoculate the cells. Based on these results, the time required for one replication cycle of
BVDV in MDBK cells was 22 hours. Note that the detection level set in these experiments was based on the lower limit of detection as determined by the standard curve.
The BVDV production in MDBK cell over a four-day incubation period was also assessed relative to ribavirin (RIB) and interferon (IFN), as shown in Figure 7.
Example 17
Evaluation of candidate antiviral compounds using RT-PCR
MDBK cells were seeded at 5 x 104 cells/ well, infected with BVDV with a MOI equal to 0.02 and grown for 22 hours in the presence of a test compound. Cells that were not treated with a test compound were considered a negative control, while ribavirin
served as a positive control. Viral RNA was extracted and analyzed by real time RT- PCR. A typical experiment, shown in Figure 4, demonstrates that the negative control and the compounds C2-MP Aldehyde, C4-MPAlddehyde, C6-MAD, F-ara-CH2-BAD, guanosine, benzyl-C2-MPA-O-mesyl and mizoribine produced comparable amounts of virus, effectively showing the test compounds as non-active. However, the cells treated with the positive control, ribavirin (RIB) or with mycophenolic acid or tiazofurin show an almost complete absence of viral RNA. Other active compounds are listed in Table 1 and/or shown in Figure 8. RIB and these active compounds reduce viral production by approximately 2 log PFU, or 99%, in the 22 hour replication period. The exact potency of these compounds cannot be deduced from this experiment, since the detection limit in this experiment is set at -0.22 log PFU and only one cycle of viral replication occurs under the stated experimental conditions.
Potencies, or the effect concentration of compounds that inhibits virus production by 50% or 90% (EC50 or EC o values, respectively), of anti-BVDV compounds were determined in a similar set of experiments, but over a broad range of test compound concentrations (0, 1, 3, 10, 33, 100 μM). The EC9o value refers to the concentration necessary to obtain a 1-log reduction in viral production within a 22 hour period. Compounds that showed potent antiviral activity are listed in Table 1 and Table 2. Toxicity data were also obtained and are included, when available. Controls were Ribavirin and the polyoxymetalate HPA-023 in these experiments.
The dose-response for ribavirin (Rib) and Tiazofurin were compared to C2-MAD 24 hours post-infection, as shown in Figure 9. The prevention of antiviral effect by exogenous addition of guanosine 24 hours post-infection was also measured to determine if the compounds were IMPDH inhibitors. As shown in Figure 10, the IMPDH activity does not always correlate with anti-BVDV activity. For example, Mizoribine is a very potent human IMPDH inhibitor ( _ = 0.004 μM), but not active against BVDV (EC90 > 100 μM), while C2-MAD is a potent IMPDH inhibitor (K, = 0.3 μM), as well as a potent inhibitor of BVDV (EC90 = 4 μM).
Table 1: a determined after 22 hours. cytotoxicity determined using either a cell-growth curve, or a colorometric assay using MTT or MTS as described by the manufacturer (Promega). ; max log reduction tested at indicated concentration (40 μM or 100 μM).
Table 2: HepG2 cells: CC50 > 50 μM for all compounds, except Benzamide riboside (CC50 = 8 μM)
PBM cells: CC50 > 50 μM for all compounds, except Benzamide riboside, C6-MPAlc and C6-MPA-O-Me (CC5o < 17 μM)
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications will be obvious to those skilled in the art from the foregoing detailed description of the invention and may be made while remaining within the spirit and scope of the invention.
Claims (1)
- WE CLAIM:A compound of the following general formula (I):(I) or its pharmaceutically acceptable salt or prodrug thereof; wherein R is(H) (HI)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR°, NR 6°Rt>7', NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6; Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8; !- 4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur;W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2j CO Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD).The compound of Claim 1, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.A compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof.A compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 and Rn is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl. A compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR13 is lower alkyl (i.e. a C\, C2, C3, C4, C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C , C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C4, C5 or C6 alkynyl) or a C3-C8 cycloalkyl.A compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl(MOM) group.A compound selected from the group consisting of the following:C4-MPAlcohol-ethyleπebis(phosphonate)or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and each R12 is independently hydrogen, alkyl or aryl.A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound of the formula(I):(I) or its pharmaceutically acceptable salt or prodrug thereof; whereinR is(II) (in)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6;Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8;W]-W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur; 5- 8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD); in a pharmaceutically acceptable carrier or diluent.9. The pharmaceutical composition of Claim 8, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.10. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier or diluent.11. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R , 10 and R is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl; in a pharmaceutically acceptable carrier or diluent.12. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR13 is lower alkyl (i.e. a Ci, C2, C3, C , C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C4, C5 or Cβ alkenyl), lower alkynyl (i.e. a C2, C3, C4, C5 or C6 alkynyl) or a C3-C8 cycloalkyl; in a pharmaceutically acceptable carrier or diluent.3. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R 1 10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; in a pharmaceutically acceptable carrier or diluent.4. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:CΦ-MPAlcohol-ethylenebisfehosphonat-)or its pharmaceutically acceptable salt or prodrug thereof, whereinX is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and each R12 is independently hydrogen, alkyl or aryl; in a pharmaceutically acceptable carrier or diluent.Ill5. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound of the formula(I):(I) or its pharmaceutically acceptable salt or prodrug thereof; wherein R is(II) (III)(IV) (V)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6; Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NRSR9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8;W^W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur;W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD); in combination with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.16. The pharmaceutical composition of Claim 15, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.17. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound of the formula: or its pharmaceutically acceptable salt or prodrug thereof, in combination with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.18. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R , 10 and R .11 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl; in combination with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.19. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR13 is lower alkyl (i.e. a Ci, C2, C3, C , C5 or C6 alkyl), lower alkenyl (i.e. a C , C3, C , C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C4, C5 or Cβ alkynyl) or a C3-C8 cycloalkyl; in combination with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.0. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compoun selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; in combination with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.1. A pharmaceutical composition for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising an effective amount of a compound selected from the group consisting of the following:C4-MPAlcohol-ethylenebis(phosphonate)or its pharmaceutically acceptable salt or prodrug thereof, whereinX is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and each R12 is independently hydrogen, alkyl or aryl; in combination with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.2. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound of the formula (I):(I) or its pharmaceutically acceptable salt or prodrug thereof; wherein R is(π) (III)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6;Z is hydrogen, halogen (F, CI, Br, I), NΗ2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8; ^-W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur;W5- 8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD); optionally in a pharmaceutically acceptable carrier or diluent.23. The method of Claim 22, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.24. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.25. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 and R11 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl; optionally in a pharmaceutically acceptable carrier or diluent.6. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR13 is lower alkyl (i.e. a Ci, C2, C3, C4, C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C , C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C , C5 or C6 alkynyl) or a C3-C8 cycloalkyl; optionally in a pharmaceutically acceptable carrier or diluent.7. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; optionally in a pharmaceutically acceptable carrier or diluent.8. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:C MPAlcohol-ethylenebisCphosphonate)or its pharmaceutically acceptable salt or prodrug thereof, whereinX is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and each R12 is independently hydrogen, alkyl or aryl; optionally in a pharmaceutically acceptable carrier or diluent.9. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound of the formula (I):(I) or its pharmaceutically acceptable salt or prodrug thereof; whereinR is(II) (HI)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6;Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8; W'-W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur;W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD); in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.30. The method of Claim 29, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.31. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound of the formula;or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.32. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 and R11 is independently hydrogen, alkyl, acyl, benzyl or19 methoxymethyl (MOM) group, and each R is independently hydrogen, alkyl or aryl; in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent,3. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR13 is lower alkyl (i.e. a C2, C3, C , C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C4, C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C , C5 or C6 alkynyl) or a C3-C8 cycloalkyl; in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.4. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.5. A method for the treatment or prophylaxis of a Flaviviridae infection in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:C4-MPAlcohol-ethylenebis(phosphonate)or its pharmaceutically acceptable salt or prodrug thereof, whereinX is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and1 ^ each R is independently hydrogen, alkyl or aryl; in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent.6. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound of the formula (I):(I) or its pharmaceutically acceptable salt or prodrug thereof; whereinR is(ii) (in)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6; Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8;W^-W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur;W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD); optionally in a pharmaceutically acceptable carrier or diluent.37. The method of Claim 22, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.38. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound of the formula: or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.39. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R .10 and R »π is independently hydrogen, alkyl, acyl, benzyl or metho a?xymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl; optionally in a pharmaceutically acceptable carrier or diluent.40. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R , 10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR is lower alkyl (i.e. a C1; C2, C3, C4, C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C , C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C , C5 or C6 alkynyl) or a C3-C8 cycloalkyl; optionally in a pharmaceutically acceptable carrier or diluent.1. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R ,ιo . is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; optionally in a pharmaceutically acceptable carrier or diluent.2. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:C4- PAlcohol-ethylenebis(pho-phonate)or its pharmaceutically acceptable salt or prodrug thereof, whereinX is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and each R12 is independently hydrogen, alkyl or aryl; optionally in a pharmaceutically acceptable carrier or diluent.3. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound of the formula (I):(i) or its pharmaceutically acceptable salt or prodrug thereof; wherein R is(π) (m)(IV) (V)X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene;Y is hydrogen, halogen (F, CI, Br, I), NH2, NHR6, NR6R7, NHOH, NHOR6, NHNH2, NR6NH2, NHNHR6, SH, SR6, OH or OR6; Z is hydrogen, halogen (F, CI, Br, I), NH2, NHR8, NR8R9, NHOH, NHOR8, NHNH2, NR8NH2, NHNHR8, SH, SR8, OH, OR8;W!-W4 are same or different, and independently methyne (-CH=), azomethyne (-N=) or sulfur;W5-W8 are same or different, and independently methyne (-CH=) or azomethyne (-N=);R1, R2, R3 and R4 are independently hydrogen, hydroxyl or fluorine;R5 is halogen (F, CI, Br, I), CN, CONH2, CO2Me, CO2Et or CO2H; andR6, R7, R8 and R9 are independently a lower alkane or alkene of 1, 2, 3, 4, 5 or 6 carbons or aryl or aralkyl; wherein the compound is specifically not tiazole-4-carboxamide adenine dinucleotide (TAD) or benzamide adenine dinucleotide (BAD); in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent.44. The method of Claim 29, wherein the compound of formula (I) is selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof, wherein X is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene.45. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound of the formula; or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent.46. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 and Rn is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group, and each R12 is independently hydrogen, alkyl or aryl; in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent.47. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R ■ 10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; each R12 is independently hydrogen, alkyl or aryl; andR is lower alkyl (i.e. a Ci, C2, C3, C , C5 or C6 alkyl), lower alkenyl (i.e. a C2, C3, C4, C5 or C6 alkenyl), lower alkynyl (i.e. a C2, C3, C4, C5 or C6 alkynyl) or a C3-C8 cycloalkyl; in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent.48. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:or its pharmaceutically acceptable salt or prodrug thereof; wherein each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent.49. A method for the treatment or prophylaxis of abnormal cellular proliferation in a host, comprising administering an effective amount of a compound selected from the group consisting of the following:C -MPAlcohol-ethylenebis(phosphonate)or its pharmaceutically acceptable salt or prodrug thereof, whereinX is oxygen, sulfur, methylene, monofluoromethylene or difluoromethylene; and each R10 is independently hydrogen, alkyl, acyl, benzyl or methoxymethyl (MOM) group; and each R12 is independently hydrogen, alkyl or aryl; in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent.50. The method of any one of Claims 22-49, wherein the host is a human.51. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for use in medical therapy.52. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of a Flaviviridae infection in a host.53. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of a Flaviviridae infection in a host.54. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection in a host.55. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection in a host.56. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of a Flaviviridae infection in a host.57. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of a Flaviviridae infection in a host.58. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection in a host.59. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other antivirally effective agent, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of a Flaviviridae infection in a host.60. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation in a host.61. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation in a host.62. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation in a host.63. Use of an effective amount of a compound of any one of claims 1-7 or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation in a host.64. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation in a host.65. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent, for the treatment or prophylaxis of abnormal cellular proliferation in a host.66. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation in a host.67. Use of an effective amount of a compound of the formula:or its pharmaceutically acceptable salt or prodrug thereof, in combination or alternation with one or more other effective antiproliferative agent, optionally in a pharmaceutically acceptable carrier or diluent, in the manufacture of a medicament for the treatment or prophylaxis of abnormal cellular proliferation in a host.8. The use of any one of claims 51-68, wherein the host is a human.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25606600P | 2000-12-15 | 2000-12-15 | |
US60/256,066 | 2000-12-15 | ||
PCT/US2001/049231 WO2002048165A2 (en) | 2000-12-15 | 2001-12-17 | Antiviral agents for treatment of flaviviridae infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002232660A1 true AU2002232660A1 (en) | 2002-06-24 |
Family
ID=22970978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002232660A Abandoned AU2002232660A1 (en) | 2000-12-15 | 2001-12-17 | Antiviral agents for treatment of flaviviridae infections |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040266723A1 (en) |
EP (1) | EP1366055A2 (en) |
JP (1) | JP2005502580A (en) |
KR (1) | KR20030081343A (en) |
CN (1) | CN1527836A (en) |
AU (1) | AU2002232660A1 (en) |
BR (1) | BR0116221A (en) |
CA (1) | CA2429352A1 (en) |
WO (1) | WO2002048165A2 (en) |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001259068A1 (en) | 2000-04-13 | 2001-10-30 | Pharmasset, Ltd. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (en) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | APPLICATION OF RIBONOUSALIC COMPOUNDS FOR TREATING FLAVIVIRUS AND PESTIVIRUS INFECTIONS |
PL207405B1 (en) | 2001-01-22 | 2010-12-31 | Isis Pharmaceuticals Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
TW200500373A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
BR0313164A (en) | 2002-08-01 | 2007-07-17 | Pharmasset Inc | compounds with the non-bicyclic system [4.2.1] for the treatment of flaviviridae infections |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
AU2004233897A1 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
SI1633766T1 (en) | 2003-05-30 | 2019-06-28 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
WO2005009418A2 (en) * | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
ATE424400T1 (en) | 2003-12-22 | 2009-03-15 | Gilead Sciences Inc | 4'-SUBSTITUTED CARBOVIR AND ABACAVIR DERIVATIVES AND RELATED COMPOUNDS HAVING HIV AND HCV ANTIVIRAL ACTION |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
JP5055564B2 (en) | 2004-06-15 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | C-purine nucleoside analogues as inhibitors of RNA-dependent RNA viral polymerase |
US20060040944A1 (en) * | 2004-06-23 | 2006-02-23 | Gilles Gosselin | 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
AU2005267421B2 (en) | 2004-06-24 | 2010-06-03 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
ATE505196T1 (en) | 2004-07-27 | 2011-04-15 | Gilead Sciences Inc | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI-HIV AGENTS |
NZ554442A (en) | 2004-09-14 | 2011-05-27 | Pharmasset Inc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
EP1877054A2 (en) * | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
JP4705164B2 (en) | 2005-05-02 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | HCV NS3 protease inhibitor |
AR057456A1 (en) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | HCV PROTEASA NS3 INHIBITORS |
JP4705984B2 (en) | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Macrocyclic peptides as HCV NS3 protease inhibitors |
WO2007075876A2 (en) | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
JP5167244B2 (en) | 2006-04-11 | 2013-03-21 | ノバルティス アーゲー | HCV / HIV inhibitors and their use |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
AU2007309544B2 (en) | 2006-10-24 | 2012-05-31 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
WO2008051477A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CA2667266C (en) | 2006-10-24 | 2015-11-24 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
MX2009004556A (en) | 2006-10-27 | 2009-07-10 | Merck & Co Inc | Hcv ns3 protease inhibitors. |
EP2083844B1 (en) | 2006-10-27 | 2013-11-27 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
AU2007335962B2 (en) | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
EP2124555B1 (en) | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
CA2696053A1 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
JP2010533699A (en) | 2007-07-17 | 2010-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Macrocyclic indole derivatives for the treatment of hepatitis C infection |
WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
EP2271345B1 (en) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
WO2009148541A1 (en) * | 2008-05-29 | 2009-12-10 | The Board Of Trustees Of The Leland Stanford Junior University | Pip-2 inhibition-based antiviral and anti-hyperlipidemic therapies |
JP2011526893A (en) | 2008-07-02 | 2011-10-20 | イデニク プハルマセウティカルス,インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
ES2393962T3 (en) | 2008-07-08 | 2013-01-03 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds. |
ME02024B (en) | 2008-07-22 | 2015-05-20 | Merck Sharp & Dohme | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
EA201100851A1 (en) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | NUCLEOSIDE ANALOGUES |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
MX2011006891A (en) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Nucleoside phosphoramidates. |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
TWI583692B (en) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
EP2461811B1 (en) | 2009-08-05 | 2016-04-20 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
RU2012122637A (en) | 2009-11-14 | 2013-12-20 | Ф.Хоффманн-Ля Рош Аг | BIOMARKERS FOR FORECASTING A QUICK RESPONSE TO TREATING HEPATITIS C |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
CN102656459A (en) | 2009-12-02 | 2012-09-05 | 弗·哈夫曼-拉罗切有限公司 | Biomarkers for predicting sustained response to HCV treatment |
CN102822175A (en) | 2009-12-18 | 2012-12-12 | 埃迪尼克斯医药公司 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
EP2552931B1 (en) | 2010-03-31 | 2014-07-23 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
BR112012024661A2 (en) | 2010-04-01 | 2015-09-15 | Centre Nat Rech Scient | compound, pharmaceutical composition and method of treating a host infected with hepatitis c virus |
EP2624826B1 (en) | 2010-10-08 | 2018-07-18 | Novartis AG | Vitamin e formulations of sulfamide ns3 inhibitors |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
CN103339136A (en) * | 2010-12-01 | 2013-10-02 | 巴伊兰大学 | Uridine di- or tri-phosphate derivatives and uses thereof |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
JP2014511875A (en) | 2011-04-13 | 2014-05-19 | メルク・シャープ・アンド・ドーム・コーポレーション | 2'-cyano-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
JP2014515023A (en) | 2011-04-13 | 2014-06-26 | メルク・シャープ・アンド・ドーム・コーポレーション | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2731433A4 (en) | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
AR088441A1 (en) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
BR112014006324B8 (en) | 2011-09-16 | 2019-02-12 | Gilead Pharmassett Llc | composition and use for hcv treatment |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CN104185420B (en) | 2011-11-30 | 2017-06-09 | 埃默里大学 | Antiviral JAK inhibitor for treating or preventing retrovirus and other virus infection |
US20140356325A1 (en) | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
WO2013177219A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
SG11201407336PA (en) | 2012-05-25 | 2015-03-30 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
TR201809048T4 (en) | 2012-10-08 | 2018-07-23 | Centre Nat Rech Scient | 2'-chloro nucleoside analogs for HCV infection. |
EP2909223B1 (en) | 2012-10-19 | 2017-03-22 | Idenix Pharmaceuticals LLC | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
RU2534613C2 (en) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014167528A1 (en) * | 2013-04-11 | 2014-10-16 | Novartis Ag | Spiropyrazolopyridine derivatives and uses thereof for the treatment of viral infections |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
PT3038601T (en) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
JP2017504060A (en) * | 2013-12-19 | 2017-02-02 | スリーエム イノベイティブ プロパティズ カンパニー | Article comprising self-assembled layer comprising nanoparticles having phosphorus surface treating agent |
CN106061984A (en) | 2014-02-13 | 2016-10-26 | 配体药物公司 | Prodrug compounds and their uses |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
ES2908332T3 (en) | 2014-07-24 | 2022-04-28 | Grace W R & Co | Crystalline form of Ribosylnicotinamide chloride |
CA2978069C (en) | 2015-03-09 | 2021-10-12 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
HRP20231155T1 (en) * | 2016-01-08 | 2024-01-05 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
ES2969496T3 (en) | 2017-08-01 | 2024-05-20 | Gilead Sciences Inc | Crystalline forms of ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl Ethyl (phenoxy)phosphoryl)-L-alaninate to treat viral infections |
US11414407B2 (en) | 2017-12-22 | 2022-08-16 | Elysium Health, Inc. | Crystalline forms of nicotinamide riboside chloride |
CA3087932A1 (en) | 2018-01-09 | 2019-07-18 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
TW202014182A (en) | 2018-04-30 | 2020-04-16 | 美商歐瑞克製藥公司 | Cd73 inhibitors |
US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
CN114796229A (en) * | 2022-05-11 | 2022-07-29 | 中国科学院大学 | Application of 6-Thioinosine in inhibition of ZIKV replication |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686234A (en) * | 1985-11-27 | 1987-08-11 | Syntex (U.S.A) Inc. | Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis |
US4748173A (en) * | 1987-01-30 | 1988-05-31 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions |
US5079600A (en) * | 1987-03-06 | 1992-01-07 | Schnur Joel M | High resolution patterning on solid substrates |
US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
AU6247594A (en) * | 1993-02-24 | 1994-09-14 | Jui H. Wang | Compositions and methods of application of reactive antiviral polymers |
US5569650A (en) * | 1993-06-11 | 1996-10-29 | Sloan-Kettering Institute For Cancer Research | C-nucleoside isosters of analogs thereof and pharmaceutical compositions |
WO1995003056A1 (en) * | 1993-07-19 | 1995-02-02 | Tokyo Tanabe Company Limited | Hepatitis c virus proliferation inhibitor |
US5727977A (en) * | 1996-03-04 | 1998-03-17 | Motorola, Inc. | Process for manufacturing a field-emission device |
US5633388A (en) * | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5891874A (en) * | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US5922757A (en) * | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
BR9712285A (en) * | 1996-10-09 | 2001-11-20 | Pharmasset Ltd | Bicyclic tetraphosphonate of triamhydrides |
CA2279963C (en) * | 1997-02-06 | 2008-04-22 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use |
DK1009732T3 (en) * | 1997-06-30 | 2003-09-22 | Merz Pharma Gmbh & Co Kgaa | 1-Amino-alkylcyclohexane NMDA receptor antagonists |
US6087231A (en) * | 1999-08-05 | 2000-07-11 | Advanced Micro Devices, Inc. | Fabrication of dual gates of field transistors with prevention of reaction between the gate electrode and the gate dielectric with a high dielectric constant |
-
2001
- 2001-12-17 EP EP01992193A patent/EP1366055A2/en not_active Withdrawn
- 2001-12-17 CA CA002429352A patent/CA2429352A1/en not_active Abandoned
- 2001-12-17 WO PCT/US2001/049231 patent/WO2002048165A2/en not_active Application Discontinuation
- 2001-12-17 KR KR10-2003-7007530A patent/KR20030081343A/en not_active Application Discontinuation
- 2001-12-17 AU AU2002232660A patent/AU2002232660A1/en not_active Abandoned
- 2001-12-17 BR BR0116221-7A patent/BR0116221A/en not_active IP Right Cessation
- 2001-12-17 JP JP2002549696A patent/JP2005502580A/en active Pending
- 2001-12-17 CN CNA018226655A patent/CN1527836A/en active Pending
- 2001-12-17 US US10/023,637 patent/US20040266723A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20030081343A (en) | 2003-10-17 |
US20040266723A1 (en) | 2004-12-30 |
WO2002048165A2 (en) | 2002-06-20 |
WO2002048165A3 (en) | 2003-05-01 |
BR0116221A (en) | 2005-09-13 |
JP2005502580A (en) | 2005-01-27 |
EP1366055A2 (en) | 2003-12-03 |
CN1527836A (en) | 2004-09-08 |
CA2429352A1 (en) | 2002-06-20 |
WO2002048165A8 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040266723A1 (en) | Antiviral agents for treatment of Flaviviridae infections | |
JP5463332B2 (en) | 2 'and 3'-nucleoside prodrugs for the treatment of flavivirus infection | |
JP5087211B2 (en) | 2 'and 3'-nucleoside prodrugs for the treatment of flavivirus infection | |
RU2525392C2 (en) | Compounds and pharmaceutical compositions for treating viral infections | |
KR20060084845A (en) | Purin nucleoside analogues for treating flaviviridae including hepatitis c | |
KR20050035194A (en) | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
CZ20024225A3 (en) | Pharmaceutical preparation | |
JP2014196336A (en) | Compound for therapy of viral infection, and pharmaceutical composition | |
TW201329096A (en) | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | |
JP2014514295A (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
MXPA04007876A (en) | Modified fluorinated nucleoside analogues. | |
JP2008535932A (en) | Nucleosides with unnatural bases as antiviral agents | |
MX2013013570A (en) | Purine monophosphate prodrugs for treatment of viral infections. | |
JP2014526474A (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
ZA200509521B (en) | Modified fluorinated nucleoside analogues | |
JP2013523765A (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
WO2015066370A1 (en) | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv | |
CN101172992A (en) | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
RU2466729C2 (en) | Compounds and pharmaceutical compositions for treating viral infections | |
RU2437892C2 (en) | Modified 2- and 3-nucleosides and use thereof to produce medicinal agent, having hepatitis c inhibiting activity |